

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

Before The Honorable Vince Chhabria, Judge

EDWARD HARDEMAN,)	
)	
Plaintiff,)	
)	
VS.)	NO. C 16-00525 VC
)	
MONSANTO COMPANY,)	
)	
Defendant.)	
_____)	

San Francisco, California
Monday, March 4, 2019

TRANSCRIPT OF PROCEEDINGS

APPEARANCES:

For Plaintiff:

ANDRUS WAGSTAFF PC
7171 W. Alaska Drive
Lakewood, Colorado 80226
BY: **AIMEE H. WAGSTAFF, ATTORNEY AT LAW**
DAVID J. WOOL, ATTORNEY AT LAW

MOORE LAW GROUP
1473 South 4th Street
Louisville, Kentucky 40208
BY: **JENNIFER MOORE, ATTORNEY AT LAW**

(APPEARANCES CONTINUED ON FOLLOWING PAGE)

REPORTED BY: Marla F. Knox, RPR, CRR
Jo Ann Bryce, CSR No. 3321, RMR, CRR, FCRR
Official Reporters

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

APPEARANCES: (CONTINUED)

For Plaintiff:

THE MILLER FIRM LLC
108 Railroad Avenue
Orange, Virginia 22960

BY: BRIAN BRAKE, ATTORNEY AT LAW

For Defendant:

WILKINSON WALSH ESKOVITZ LLP
2001 M Street, NW - 10th Floor
Washington, D.C. 20036

**BY: BRIAN L. STEKLOFF, ATTORNEY AT LAW
RAKESH N. KILARU, ATTORNEY AT LAW
TAMARRA MATTHEWS JOHNSON, ATTORNEY AT LAW
JULIE RUBENSTEIN, ATTORNEY AT LAW
CALI COPE-KASTEN, ATTORNEY AT LAW**

PROCEEDINGS

1 Monday - March 4, 2019

7:58 a.m.

2 P R O C E E D I N G S

3 ---000---

4 (Proceedings were heard out of presence of the jury:)

5 **THE COURT:** Hi, everybody. This is on the record.

6 So we just got a call from a juror, number -- is it the
7 last one?

8 **MS. WAGSTAFF:** In the back row?

9 **THE COURT:** Front row, the last person.

10 **MS. MOORE:** Ms. Torres.

11 **THE COURT:** She thinks she has food poisoning, and she
12 can't come in today. My proposal is that since we appear to be
13 a little bit ahead of schedule, we cancel -- we immediately get
14 on the phone to the other jurors; tell them to turn around;
15 that we won't be having trial today and they should plan on
16 resuming tomorrow.

17 Any objection to that?

18 **MS. MOORE:** No objection, Your Honor.

19 **THE COURT:** Then I have a couple things to speak to
20 you-all about, so I will be back after we call the jurors.

21 Kristen and Jordan, maybe you can split up the jurors and
22 call them.

23 **THE CLERK:** Court is in recess.

24 (Recess taken at 7:59 a.m.)

25 (Proceedings resumed at 8:22 a.m.)

PROCEEDINGS

1 (Proceedings were heard out of presence of the jury:)

2 **THE COURT:** Okay. So I have a couple issues I'm ready
3 to talk to you-all about, and then if you have -- if you have
4 anything, you can raise it as well.

5 The first is the Arber testimony. I went back and looked
6 over Arber's reports and, you know, Mr. Kilaru, I'm not sure
7 what you were trying to feed me on Friday, but whatever it was
8 was inconsistent with what Arber had said in his report, not
9 just not disclosed but inconsistent.

10 You appeared to be saying that Dr. Arber was prepared to
11 offer an opinion that the pathology results hinted at
12 hepatitis C, and that's contrary to what he said in his report.
13 He said that there is nothing in the pathology that indicates a
14 cause for Mr. Hardeman's NHL. So the opinion that you were
15 attempting to describe on Friday is not admissible. He cannot
16 present that opinion.

17 I also think that to the extent Arber intends to offer the
18 opinion that he did disclose in his report, which is that the
19 pathology does not indicate any particular cause of
20 Mr. Hardeman's NHL, my sense about that -- you know, continuing
21 from our discussion on Friday -- is that, as I understand it,
22 that's not a contested issue.

23 The Plaintiffs have not disputed that you cannot discern
24 from the pathology what caused Mr. Hardeman's NHL. If
25 Dr. Arber wants to mention briefly that during his testimony

PROCEEDINGS

1 that it's -- that the pathology doesn't suggest a cause, I
2 think that's fine. If you want to establish during his
3 testimony that that's uncontested, that none of the experts
4 disagree about that, that's fine; but offering a full-length
5 opinion on that or a full-fledged opinion on that explaining
6 why and the ins and outs of why, I think is a waste of the
7 jury's time because it is uncontested. So I would exclude him
8 from doing more than what I just described on that point.

9 **MR. KILARU:** Can I briefly address those points?

10 **THE COURT:** Sure.

11 **MR. KILARU:** So on the first -- I actually have the
12 report in front of me now which I think will help -- the line,
13 I believe, Your Honor is referring to is in a supplemental
14 report where he says There are no features that would suggest a
15 specific cause for this lymphoma, and Dr. Arber did not intend
16 -- and if I said that he did, I apologize -- does not intend to
17 testify to --

18 **THE COURT:** I think there are a number of places in
19 the Arber report where he says something along those lines,
20 right?

21 **MR. KILARU:** Well, he says -- well, that is a line in
22 the supplemental report; and so I think that just -- I started
23 there because I think that most nearly described what you said.

24 **THE COURT:** Well, I mean let's look at paragraph 25 of
25 his initial report --

PROCEEDINGS

1 **MR. KILARU:** Okay.

2 **THE COURT:** -- which says, There are no pathological
3 features to suggest a cause of his lymphoma.

4 **MR. KILARU:** Right, and I think it's true that he
5 believes that -- I think what he would say is I cannot
6 distinguish Mr. Hardeman's NHL from an idiopathic cause of NHL.
7 I think if you look through other portions of the report where
8 he talks about -- for example, if you look earlier in
9 paragraph 18, he talks about the results of a fish test,
10 particularly a DCL6 rearrangement. And if you look then, if
11 you keep going down, to paragraph 23, he talks extensively
12 about hepatitis C and the potential of hepatitis C to cause
13 mutations over his many years of exposure.

14 **THE COURT:** I understand that. I'm not saying that he
15 can't testify that the Plaintiff's experts improperly ruled out
16 hep C. I'm just saying that he can't testify that the
17 pathology suggests that the cause was hep C, and that would be
18 consistent with what he said in his expert report, not merely
19 undisclosed but inconsistent.

20 **MR. KILARU:** Well, specifically I think what he would
21 say is not that this DCL6 issue that we talked about makes
22 clear that hepatitis C is the cause. I think what we intend
23 what he would like to say -- based on his review of the
24 literature and I think this is consistent with his report -- is
25 that there is evidence suggesting that DCL6 at a low level of

PROCEEDINGS

1 correlation is correlated with hepatitis C, and there is no
2 evidence suggesting that that is correlated with Roundup. I
3 think those specific words do not appear in the report, that's
4 true. But I do think he talks about the mutation, and he makes
5 clear that Plaintiff's experts have failed to reliably rule out
6 hepatitis C as a cause.

7 **THE COURT:** I understand the argument. He is not
8 permitted to offer that opinion. It is excluded.

9 **MR. KILARU:** Okay. On the second point, Your Honor,
10 as to -- I guess the question is sort of what the bounds are
11 around his testimony. I think that we have heard extensive
12 testimony and I think some repetitive testimony from the
13 Plaintiff's experts about the same set of epidemiologic
14 studies, it is not really disputed what their take is on those
15 studies. I think Dr. Weisenburger is going to comment on that
16 as well.

17 **THE COURT:** I mean, part of this depends on what
18 Weisenburger says, of course. It may be what your expert
19 testifies to -- can testify to, may depend in part on what
20 Weisenburger testifies to.

21 **MR. KILARU:** Right. I guess that goes to the previous
22 point because I think if Dr. Weisenburger, who never looked at
23 the slides, starts talking about genetic mutations and features
24 of pathology, I think that would open the door to Dr. Arber
25 being able to do so as well.

PROCEEDINGS

1 **THE COURT:** Well, the problem is the -- as I
2 understand it, you know, yes, there are genetic mutations; but
3 there is nothing to link those genetic mutations to
4 hepatitis C, and nobody has offered any opinion that those
5 genetic mutations are caused by hepatitis C. So, you know, to
6 the extent that Dr. Arber is trying to sneak in an opinion that
7 the -- you know, the fact that there are these genetic
8 mutations suggests that it was hepatitis C, that is something
9 that was not disclosed, and, again, contrary to the report that
10 he prepared.

11 **MR. KILARU:** I understand that -- that position,
12 Your Honor. I was making a different point which is if
13 Dr. Weisenburger tries to talk about those same topics, which
14 are also not disclosed in his report and not something he has
15 opined on before, then we think the door would be open for
16 Dr. Arber to do so as well. I don't think it can only be
17 Dr. Arber who is not allowed to talk about the pathological
18 features and what those mutations are consistent or not
19 consistent with.

20 **THE COURT:** Well, I don't recall Dr. Weisenburger ever
21 having offered an opinion about the pathology, other than
22 nobody can tell from the pathology how the NHL was caused.

23 **MS. MOORE:** That's correct, Your Honor.

24 **THE COURT:** If I'm misremembering that, fine. But I
25 don't recall him testifying to anything other than that

PROCEEDINGS

1 regarding the pathology.

2 **MR. KILARU:** Okay.

3 **MS. MOORE:** Your Honor --

4 **THE COURT:** The --

5 **MR. KILARU:** The reason I raised this point is last
6 night we received exhibits and demonstratives for
7 Dr. Weisenburger and some even talk about DCL2, which is one of
8 the mutations. So to the extent they are going to go into
9 that, which I think is not disclosed and not something he
10 talked about --

11 **THE COURT:** Well, the idea that there is a mutation
12 is -- to me is very different from the idea of what caused the
13 mutation.

14 **MR. KILARU:** Well, the mutation -- the figures we
15 got -- and, again, I don't know how they intend to use them.
16 We just got this disclosed, so I'm raising this point because I
17 do think that they open the door. It would change the scope of
18 Dr. Arber's testimony. But the charts we got were about
19 whether the mutations that are present are consistent with
20 certain findings about hepatitis C and the level of response of
21 someone to -- the level of response based on treatment that
22 someone has, how sustained virological response relates to DCL2
23 mutations present in pathology. Now, if that testimony is
24 offered -- if those exhibits are offered -- I don't think there
25 is any meaningful distinction between that and Dr. Arber

PROCEEDINGS

1 talking about whether those same morphological features of the
2 pathology have anything to do with hepatitis C in a different
3 way.

4 **THE COURT:** Well, I think on that point, I'm just not
5 sure that I'm capable of responding to that meaningfully in a
6 vacuum, not having seen the slides, not having heard what
7 Dr. Weisenburger is going to testify to. You know, I just
8 don't think I can give you a meaningful response to that.

9 **MR. KILARU:** Understood, Your Honor.

10 **THE COURT:** All I can say is that, you know, that
11 Dr. Arber can offer an opinion on hepatitis C and he can -- he
12 can say that the -- you know, the Plaintiff's experts
13 improperly ruled out hepatitis C, but part of that is not that
14 the pathology results support the view that the NHL was caused
15 by hepatitis C because that was inconsistent with what he said
16 in his report. That is my ruling on Dr. Arber.

17 **MR. KILARU:** Okay.

18 **MS. MOORE:** Your Honor, one thing really quickly.
19 Would that also apply to any opinion that Dr. Arber may provide
20 with respect to hepatitis B?

21 **THE COURT:** Well, I mean it has to --

22 **MS. MOORE:** I just wanted to clarify.

23 **THE COURT:** -- because of what he said in his report.

24 **MS. MOORE:** Okay. Thank you, Your Honor.

25 **MR. KILARU:** Your Honor, just on the other point, just

PROCEEDINGS

1 so I have clarity -- I understand you are saying he can talk
2 briefly about the pathology -- I guess, the question is what
3 does that encompass? I think we intended to have him show the
4 jury a small -- briefly show the jury a small subset of
5 Mr. Hardeman's pathology and walk through what he sees. I
6 think that would be appropriate. I don't think it would be a
7 waste of the jury's time. We don't intend for it to go on very
8 long. We think it will be useful for the jury to see actual
9 medical evidence in this case, and especially given --

10 **THE COURT:** But if it is not in dispute -- if it is on
11 a topic that is not in dispute, what is the point of taking the
12 time to walk the jury through it? I mean, as I have said, he
13 can say -- I'm guessing the Plaintiffs would not object to him
14 saying that there is nothing in the pathology that would give
15 us a clue about how the NHL was caused.

16 **MS. MOORE:** That's correct, Your Honor.

17 **THE COURT:** Okay. And I'm guessing the Plaintiffs
18 would also not object to you eliciting testimony from Arber
19 that nobody -- none of the experts in this case have argued
20 to -- on either side have argued to the contrary.

21 **MS. MOORE:** That's correct, Your Honor.

22 **THE COURT:** Okay. So you can elicit that. That's two
23 questions and two answers. And after that, what is the point?

24 **MR. KILARU:** Because another pathologist is going to
25 come in, I guess, tomorrow and talk about -- rely on his

PROCEEDINGS

1 experience as a pathologist, and he will say -- well, as I
2 understand him to say, there is nothing in the slides that
3 allows me to conclude Roundup is the cause; but nevertheless
4 I'm concluding that Roundup caused Mr. Hardeman's NHL.

5 **THE COURT:** Right. But for reasons based on the
6 material other than the slides.

7 **MR. KILARU:** Right.

8 **MS. MOORE:** Right.

9 **THE COURT:** So what is the point of bringing an expert
10 in to walk the jury through -- to prove what Weisenburger has
11 said, which is that there is nothing in the slides that gives
12 me the ability to determine what caused the NHL? Why would
13 you -- why would it be appropriate for you to bring in an
14 expert to walk through -- to prove what the Plaintiff's expert
15 has said?

16 **MR. KILARU:** Because, Your Honor, one, we think that
17 point helps us. So it is part of our case to show --

18 **THE COURT:** You can talk about it until the cows come
19 home in your closing argument, but the point is we only -- we
20 only offer -- we only present expert opinions to the jury when
21 those expert opinions would be helpful to the jury. And an
22 opinion on why everybody agrees that you can't tell from the
23 pathology how the NHL was caused is not helpful to the jury.

24 **MR. KILARU:** Your Honor, with that I think we
25 respectfully disagree. Our position on why it is helpful is

PROCEEDINGS

1 because that is literally what pathologists do. It is not what
2 Dr. Weisenburger does. They don't just look at slides and
3 dismiss them and then move on with their day. They actually
4 look at the slides. They actually make diagnoses based on the
5 slides.

6 I think what Dr. Arber doing that would do is, first of
7 all, help rebut the methodologies that Dr. Weisenburger has
8 presented, which are -- I'm not going to look at the slides and
9 rule them out and look at other literature -- I think Dr. Arber
10 showing a jury what a pathologist actually does is helpful for
11 them to understand the distinction between our expert and their
12 expert as opposed to verbally saying, There is nothing in the
13 slides.

14 **THE COURT:** Okay. I understand that. There is
15 nothing in my ruling that precludes you from cross-examining
16 Weisenburger on what pathologists usually do and, you know,
17 that -- and cross-examining him on the fact that his opinion is
18 not based on sort of the heartland of what pathologists usually
19 do. That's fine.

20 And he will, I'm sure, respond, Yeah, but I'm also
21 qualified in these other areas. And in terms of what
22 pathologists usually do, we can't -- we don't have any clues
23 about what caused Mr. Hardeman's NHL from that -- which, again,
24 makes it unnecessary for you to present an expert opinion about
25 that. So certainly you can cross-examine Dr. Weisenburger

PROCEEDINGS

1 about that, and my ruling doesn't preclude you from doing that.

2 **MR. KILARU:** Okay.

3 **MS. MOORE:** Thank you, Your Honor.

4 **THE COURT:** So that's Dr. Arber.

5 Now, let's go to the Parry report. On the Parry report my
6 view about -- my fundamental view about the Parry report is
7 that the Parry report was initially excluded -- was excluded
8 pretrial based on the assumption that Monsanto would not be
9 contesting the genotoxicity issue. Monsanto is contesting the
10 genotoxicity issue; and, therefore, testimony about the Parry
11 report can come in. In other words, the door has been opened
12 to the Parry report.

13 The next question is: What is the appropriate way to
14 permit the Plaintiffs to present evidence about the Parry
15 report given that there is a very serious 403 issue here, you
16 know, the classic quintessential tail-wagging-the-dog problem.

17 And I think that the appropriate way to permit the
18 Plaintiffs to bring evidence in about the Parry report is two
19 things: One, the Portier testimony or a portion of the Portier
20 testimony that Monsanto submitted; and two, permitting the
21 Plaintiffs to briefly get into the -- the IARC's conclusion
22 regarding genotoxicity through Dr. Weisenburger.

23 So nothing extensive, but just briefly the IARC's -- you
24 know, the -- during the Portier testimony, the jury learned
25 sort of a one-sentence conclusion that the European regulatory

PROCEEDINGS

1 agency reached about genotoxicity. And similarly in light of
2 that, I think it would be appropriate for Weisenburger to share
3 with -- is he testifying about genotox? I can't remember.

4 **MS. MOORE:** Yes, Your Honor.

5 **THE COURT:** Okay. To share with the jury the sort of
6 bottom-line conclusion of the IARC regarding genotox, and I
7 can't remember exactly what that conclusion was; but it was in
8 Ms. Wagstaff's opening slide.

9 So in other words, Monsanto has opened the door to that
10 limited amount of information about IARC's conclusion about
11 genotox. That would be -- and then with respect to Portier's
12 testimony -- let me pull it up here.

13 **MS. WAGSTAFF:** Your Honor, if I may hand you the
14 Martens testimony.

15 **THE COURT:** Sure. But let me just finish this thought
16 before you get there.

17 **MS. WAGSTAFF:** Sure.

18 **THE COURT:** So with respect to Portier's testimony, I
19 would think what we are talking about allowing in, beginning on
20 page 772, line 19 down to page 774, line 13 -- sorry, line 17.
21 And then we would remove line 18 on 774, down to the bottom of
22 774, and then we would resume again on line 2 on page 775. And
23 then go down to line 21 of page 776 -- sorry. What line did I
24 just say?

25 **MS. WAGSTAFF:** 21 of 776.

PROCEEDINGS

1 **THE COURT:** Yeah. And then I think line 22 through 25
2 would not be included, page 776. So applying the Rule 403
3 principles that we have been talking about -- and then back in
4 would be -- starting on line 1 of page 777, that would come in,
5 and then go down to line 16 of 777.

6 So my view is that that testimony should be allowed in.
7 And like I said, Weisenburger could be asked about it briefly,
8 if you bring in the IARC's conclusion about genotox through
9 Weisenburger. That's my view. It sounds like you wanted to
10 argue against that.

11 Kristen, do you have that in front of you?

12 **THE CLERK:** Sorry.

13 **THE COURT:** Do you have that?

14 **MS. WAGSTAFF:** Your Honor, I just wanted to explain
15 what we did with respect to Dr. Martens, and why -- I
16 understand what your ruling is, and I'm not necessarily arguing
17 against it -- but I just want to ask one clarifying question.

18 With your order here -- or with your ruling that you just
19 made, the exhibits -- I just don't see -- I have in front of me
20 their Exhibit A, which is a portion of this. Is your order
21 that the Parry report would then go back to the jury?

22 **THE COURT:** I was assuming not.

23 **MS. WAGSTAFF:** Okay.

24 **THE COURT:** I mean, you could argue for it, but I was
25 assuming not. Again, trying to strike the balance -- the 403

PROCEEDINGS

1 balance here that probably the -- if the -- if that report were
2 admitted as an exhibit, then you would be probably sending us
3 down that rabbit hole; and Monsanto would want to bring in a
4 bunch of other stuff about the Parry report and sort of how
5 things developed since the Parry report. And the point that I
6 want to make is that, you know, the -- I do think it is
7 appropriate for you to be able to rebut Monsanto's assertions
8 and implications about the genotox evidence with the fact of
9 this report and the conclusions that -- the recommendations
10 that were reached in the report, but I do think that it is
11 still not centrally relevant to the genotox issue. I don't
12 think it is nearly as relevant as some of the other testimony
13 that Dr. Portier gave about the genotoxicity evidence, for
14 example.

15 So the point is that, you know, we don't want to -- again,
16 we don't want the tail to start wagging the dog. And I take
17 Monsanto's proposal about including this portion of the Portier
18 evidence to mean -- of the Portier testimony to mean, Well, if
19 we do not believe that we opened the door to anything, but if
20 you, Judge, disagree and you want to cure it, here is the way
21 to cure it that is not going to send us down that rabbit hole
22 and is not going to force us to start putting in a bunch of
23 evidence about how things developed after the Parry report.

24 Do I understand that correctly?

25 **MR. STEKLOFF:** I will have more to say, but yes, I

PROCEEDINGS

1 think that's true with Dr. Portier. I think -- one of the
2 things I might push back on at the moment is allowing
3 Dr. Weisenburger to say the IARC conclusion, because that's a
4 whole other step that is -- that paints a completely incomplete
5 picture when not just -- I mean, this EFSA letter, which I
6 would like to describe in a moment, was a specific response to
7 something Dr. Portier himself wrote. If we are going to
8 introduce what IARC did -- since IARC, a number of regulatory
9 bodies including EPA, including Health Canada, including
10 European bodies have come out and disagreed with IARC about
11 genotoxicity, so I don't think -- I realize now we are maybe
12 sort of slicing and dicing in different ways, but I think the
13 IARC part --

14 **THE COURT:** Fair enough. So let's bookmark the IARC
15 part for a moment. That was your point about submitting that
16 Dr. Portier testimony, correct?

17 **MR. STEKLOFF:** Yes, Your Honor.

18 **THE COURT:** Okay. All right. So, anyway, that's --
19 that was my thinking there, and my assumption was that the
20 Parry report would not come in, but you would be able to
21 establish that Monsanto -- one of Monsanto's internal people
22 reached some conclusions about the genotoxicity evidence in
23 1999.

24 **MS. WAGSTAFF:** Can I have a minute to talk to my team
25 about this?

PROCEEDINGS

1 **THE COURT:** Sure.

2 (Whereupon, a brief pause was had.)

3 **MS. WAGSTAFF:** I don't know if we want to move on the
4 to the *Knezevich & Hogan* and re-visit this after.

5 **MR. STEKLOFF:** I have some things to say about this
6 first.

7 **THE COURT:** Well, I'm not ready to talk about
8 *Knezevich & Hogan* yet.

9 **MS. WAGSTAFF:** Okay.

10 **THE COURT:** Go ahead.

11 **MR. STEKLOFF:** So understanding where you are, I still
12 think it would be -- I would just like to briefly remind the
13 Court how Dr. Portier's testimony played out, because there is
14 one thing that we didn't highlight in our letter yesterday, is
15 what happened on his direct examination before we allegedly
16 opened the door.

17 In his direct examination he -- Dr. Portier at page 35 is
18 asked what IARC's conclusion was about glyphosate. He says
19 that IARC's conclusion -- was that for glyphosate
20 specifically -- IARC's conclusion was, for glyphosate was
21 that --

22 **MS. WAGSTAFF:** Where are you reading?

23 **MR. STEKLOFF:** On page 35, line 1 through 18.

24 And he says was, For glyphosate was that probably
25 carcinogenic to humans, humans which is a classification that

PROCEEDINGS

1 has a full categorization to it and rules under which it is
2 created.

3 And then he goes onto discuss it being a probable human
4 carcinogen, that that's -- there are five classifications.
5 That is the second highest.

6 And then he goes on to ask, Now following the IARC
7 classification, do you know if there has been any scientific
8 response by regulatory agencies to IARC?

9 He says, There has been a lot.

10 And then turns to this letter -- what I'm now sort of
11 paraphrasing -- what actions did you take? And he explains
12 that he wrote to the European Union's equivalent of the EPA.

13 He then publishes in front of the jury the letter that he,
14 with approximately 95 scientists sent. He uses the journal
15 version as opposed to the letter version -- but it is the same
16 content -- to show that he sent this letter to the European
17 Commission to try to persuade them post-IARC that their view on
18 glyphosate was wrong. We know from opening, that IARC has
19 factored in with the epidemiology, the animal studies, and the
20 genotoxicity studies. We have also --

21 **THE COURT:** But opening statements are not evidence.

22 **MR. STEKLOFF:** Understood.

23 **THE COURT:** The jury is well aware.

24 **MR. STEKLOFF:** Understood.

25 But I still think that that happened. I know that that

PROCEEDINGS

1 happened.

2 I also think that we then saw the three stools -- where he
3 is walking through animal studies, epidemiology and
4 genotoxicity in detail during the three legs of the stool,
5 during his direct examination. But what I want to highlight is
6 that when he is then shown the letter -- and this is the letter
7 that -- where that is described by Dr. Portier is, We were
8 challenging when EFSA. EFSA was in the process of rereviewing
9 glyphosate when IARC did their review. In the IARC review EFSA
10 already said that they didn't think there was a problem with
11 glyphosate. So when IARC came out, it created a conflict with
12 EFSA, and he goes on.

13 So Mr. Wisner pulls up a portion of the letter that is
14 sent and says, So if you look at the last page here -- I will
15 call it out. Hopefully you can read it on your screen -- it
16 reads -- so now this is quoting the letter: The most
17 appropriate and scientifically-based evaluation of the cancer
18 reported in humans and laboratory animals as well as supportive
19 mechanistic data.

20 So he is writing a letter to Europe, highlighting the
21 human studies, the animal studies and the mechanistic studies,
22 is that glyphosate is a probable human carcinogen. On the
23 basis of this classification summary, on the basis of this
24 conclusion, and in the absence of evidence to the contrary, it
25 is reasonable to conclude that glyphosate formulations should

PROCEEDINGS

1 also be considered like human carcinogens. Did you see that?

2 Yes, I --

3 And then that's where Mr. Wisner turns to highlighting *De*
4 *Roos*, Dr. De Roos and Dr. Lynch.

5 So in his direct, he is shown this letter. He has said
6 that this is following the IARC review, and the IARC
7 classification. And then says, Based on that, I wanted to go
8 to tell Europe they are wrong about human studies, animal
9 studies and the mechanistic studies.

10 In our cross -- to be clear what we did -- he was showed
11 that Europe disagreed in a conclusion, and then we had that
12 second line that was shown and that was corrected. And then
13 there were literally two questions with nothing shown about the
14 fact that Europe disagreed on genotoxicity.

15 The notion that that opens the door to IARC's conclusion,
16 specific conclusion on glyphosate, and all of this Parry
17 stuff -- I mean, I don't think -- I have gone back to the
18 January 28th hearing, that the suggestion was that we could
19 just -- that basically we had to stipulate to the genotoxicity
20 studies, the notion that we couldn't present any evidence that
21 there is a dispute about genotoxicity opens the door to Parry,
22 given all the 403 issues, and that this happened in 1999, and
23 that IARC and the regulatory bodies are looking at a much
24 broader universe of studies that have come out and have been
25 discussed since 1999. So we are not even comparing apples to

PROCEEDINGS

1 apples. We are comparing apples to oranges.

2 I think that we -- I don't think we opened the door. And
3 I actually think what our first suggestion is if you think we
4 opened the door is to say, You can consider Europe disagreed
5 with Dr. Portier. You should not specifically consider that
6 they disagreed with him on genotoxicity because once you open
7 the door on this Parry stuff, whether we -- let's put IARC to
8 the side. Whether you even just use the Dr. Portier testimony,
9 we are getting into a -- a whole rabbit hole where we then
10 would have to tell the jury. I think, when Europe made this
11 decision, they were considering many things beyond the initial
12 studies that were available in 1999 that Dr. Parry was looking
13 at, that Europe isn't the only one that came to this conclusion
14 and disagrees with Dr. Portier.

15 I mean, the whole context of that January 28 top three
16 hearing would be -- this would be when we said -- when I went
17 back to the transcript and the full colloquy wasn't in the
18 letter, but it was -- by Mr. Wisner, said, I know what happened
19 in Johnson, and they got up and said, EPA, EPA, EPA. They made
20 a huge deal that the EPA disagrees constantly with
21 genotoxicity, that is portraying a different thing than I think
22 what is happening here.

23 If the argument was if we came into this trial and said,
24 The whole world disagrees on genotoxicity, and what Dr. Portier
25 is saying puts him completely at the margins with everyone,

PROCEEDINGS

1 maybe we would have opened the door. We have not even come
2 close to that in this trial. We are not going to do that with
3 our experts who we are calling in our case. We are not calling
4 a single expert on genotoxicity.

5 **THE COURT:** You could. I mean, you certainly would be
6 entitled to.

7 **MR. STEKLOFF:** Right. And we would open the door and
8 re-visit the Parry issue based on the state of where we are
9 now --

10 **THE COURT:** Right.

11 **MR. STEKLOFF:** -- where we haven't done that.

12 **THE COURT:** The state of where we are now is that
13 Monsanto has taken the position in this trial that -- through
14 various questions that Dr. Portier's position on genotoxicity
15 is incorrect, right? I mean, isn't that fair?

16 **MR. STEKLOFF:** I'm not sure that that's fair. I think
17 that I said in opening -- and I know opening is not evidence --
18 that the study -- the focus of this case should be on the human
19 studies. And I showed that slide that was also shown to
20 Dr. Portier during his cross-examination from the World Health
21 Organization group that he was involved in; that if human study
22 data is available, that's -- I'm again, paraphrasing -- that is
23 the priority data that you should be looking at.

24 Then during his cross-examination, there were some
25 questions about, for example, that Paz-y-Mino study to show,

PROCEEDINGS

1 well, you said one thing. There were further developments
2 there. So I think what -- I think what the evidence is thus
3 far is that mechanistic studies don't really tell you a lot
4 about geno -- about general causation, and you should be
5 focusing on the human studies. I think that's the first thing
6 we are saying.

7 And I think the second thing we are saying --

8 **THE COURT:** Okay. But let me stop you there. Even
9 just that, even just that, look, the genotoxicity evidence does
10 not tell you anything or barely tells you anything about the
11 issue of causation. Well, Monsanto has a report from a doctor
12 that it hired that -- that raised concerns about the
13 genotoxicity of glyphosate.

14 So it seems to me that you are -- you have already said
15 something to the jury -- even before we get to your second
16 point, you have already said something to the jury that is
17 contradicted to a degree by an internal Monsanto document. And
18 so why shouldn't they be able to cast doubt on Monsanto's
19 assertion to the jury that genotox doesn't matter by
20 establishing that Monsanto hired a doctor to -- or hired an
21 expert to look at the issue of genotoxicity in the late '90s
22 and the expert raised concerns about genotoxicity?

23 **MR. STEKLOFF:** Because it doesn't change -- because we
24 have heard about Dr. Portier's -- what Dr. Parry concluded
25 doesn't change the argument that I just made. The argument of

PROCEEDINGS

1 let's assume that Dr. Parry's view was correct at the time, it
2 wouldn't change what I would say in closing, which is that --

3 **THE COURT:** It wouldn't change what you would say in
4 closing, but it may cast doubt on the idea that genotox doesn't
5 matter, right? I mean, Monsanto itself investigated genotox --
6 hired somebody to investigate genotox, and that person
7 concluded that genotox -- that it's possibly genotoxic. I
8 mean, so doesn't -- it seems to me that that cuts against the
9 assertion that Monsanto has already made to the jury
10 effectively that genotox doesn't matter.

11 **MR. STEKLOFF:** I guess the issue there then, Judge --
12 Your Honor, is that the motion that we have to -- that we had
13 to go through this trial without mentioning genotoxicity in any
14 way, because if we mention it, we are not going to agree that
15 glyphosate is genotoxic.

16 So if we in any way challenge the validity of the
17 genotoxicity determination or the strength of the determination
18 or the relevance of the determination, that that blows open the
19 door about a 403 issue.

20 **THE COURT:** Not blow open the door. I mean, this is
21 hardly blowing open the door. This is accepting your proposal
22 to open the door a crack as opposed to blowing open the door.

23 **MR. STEKLOFF:** Well, I guess the -- and I -- to be
24 clear, you know, at some point -- I don't want to suggest that
25 we want to do something that blows the door open even further,

PROCEEDINGS

1 so I think the line -- if you are going to disagree with my
2 argument and draw a line somewhere and say something needs to
3 come in, I do think that the problem is that telling this part
4 of the Parry story, even through Portier, which is clearly more
5 appropriate under 403 in our view than the Martens' testimony,
6 which we will get to -- still tells an incomplete story because
7 now we have asked --

8 **THE COURT:** I think that's true. And it's
9 Monsanto's -- of course, as always has been the case, Monsanto
10 has the right to call its own genotoxicity expert; testify -- I
11 mean, you have designated genotoxicity experts. You have
12 presented genotoxicity experts at Phase One. You have the
13 right -- you know, you have the right to present evidence on
14 this if you wish and blow the door open further if you wish.
15 But the -- you know, that's not the issue. But I thought that
16 you had proposed this Portier testimony as a -- as sort of a
17 backup proposal for you that would allow us to prevent the tail
18 from wagging the dog, the Parry tail to wag the dog of this
19 trial.

20 **MR. STEKLOFF:** That's fair. And maybe I'm more
21 concerned then about the IARC classification in a way, am I
22 allowed to cross Dr. Weisenburger with the fact that EPA and
23 Health Canada and Europe, beyond the letter to Dr. Portier,
24 have disagreed with IARC?

25 **THE COURT:** Yeah, I hadn't really thought that

PROCEEDINGS

1 through. I mean, you may be right about that. It may be that
2 they don't want to go down that road. I don't know. No, they
3 probably do want to go down that road, but that may be right.

4 I mean, it may -- to allow that kind of
5 cross-examination -- of course, you would have to be able to
6 cross-examine Weisenburger along those lines; and to allow that
7 kind of cross-examination may also create the problem of, you
8 know, making this a trial about the regulatory agencies, which
9 we established at the outset this was not going to be.

10 So anyway, okay. I understand that point. I will think a
11 little further about that issue.

12 **MS. WAGSTAFF:** Your Honor --

13 **THE COURT:** But my ruling stands on the Portier
14 testimony. That's coming in as I described it.

15 **MR. STEKLOFF:** I have just one question on that.

16 **THE COURT:** Yeah.

17 **MR. STEKLOFF:** There were --

18 **MS. WAGSTAFF:** Your Honor, while he is looking for his
19 notes, if I may, just in the opening statement, which I know is
20 not testimony, there was a slide I'm showing you by
21 Mr. Stekloff that talks about that the EPA has first approved
22 it in 1975; reaffirmed it before IARC, and reaffirmed it
23 multiple times after IARC. And the EPA doesn't just -- sorry,
24 this is Exhibit 1 to -- or 2 to our *Knezevich & Hogan* letter
25 that we will talk about later -- but this EPA doesn't just look

PROCEEDINGS

1 at human studies. So we think also that that further opens the
2 door in their argument, sort of supporting what you just said.

3 **THE COURT:** Well, no, they didn't get into what EPA
4 looked at. They just said that the EPA reaffirmed it. They
5 didn't -- in opening, they didn't get into the manner by which
6 the EPA reached that conclusion. So I disagree with that
7 point.

8 **MS. WAGSTAFF:** Okay. Thank you, Your Honor.

9 And I understand your ruling, and I will just say on the
10 Dr. Martens' testimony that I have just handed you, we were
11 very narrow in what we did. And, as you know, the actual --
12 there are a couple different steps of the Parry report. And
13 the final step being the recommendations that Dr. Parry gives
14 and whether or not Monsanto complied with those. We did not
15 include those in our cuts, just so you know if you are inclined
16 to go back and look at that.

17 And with that, I will accept your ruling.

18 **THE COURT:** Okay. So that will be the ruling.
19 Portier testimony, as I described it, can come in.

20 And I will think further about the IARC issue. I think
21 that may not have been a good idea on my part to volunteer that
22 to the Plaintiffs. So I will let you know about that. Is
23 there anything else -- and as I said, on the mouse study, I'm
24 not ready to talk about that yet. I will spend some newly
25 found free time today looking at that.

PROCEEDINGS

1 And then is there anything else that you would like to
2 talk about today?

3 **MS. WAGSTAFF:** I have one last thing on the Dr. Parry
4 story. I assume this is not prejudice as to be able to bring
5 Dr. Martens' testimony in Phase Two.

6 **THE COURT:** No. I mean, I haven't looked at it with
7 an eye towards Phase Two, but certainly not.

8 **MS. WAGSTAFF:** Okay.

9 **THE COURT:** I mean, it seems like, you know, there is
10 not going to be a ton that is inadmissible in Phase Two, which
11 reminds me, we need to talk about setting some deadlines for
12 depo designations for Phase Two and stuff because, you know, I
13 don't -- maybe we should work on that issue now because, you
14 know, the jury will be -- will deliberate on the causation
15 question. And if they come back yes on causation, you are
16 going to opening statements on Phase Two first thing the next
17 morning; and you have to be ready with your case first thing
18 the next morning. We are not going to have any delays.

19 **MS. MOORE:** We understand.

20 **THE COURT:** So in light of that, what -- you know, it
21 seems like we should start talking about the plan for
22 Phase Two.

23 Do you have a plan as of now for which witnesses you are
24 going to call for Phase Two and whose testimony you are going
25 to put in by depo designation and stuff?

PROCEEDINGS

1 **MS. WAGSTAFF:** Your Honor, we have a few live
2 witnesses that we are waiting for orders from Your Honor on. I
3 think it is Dr. Benbrook.

4 **THE COURT:** Oh, yeah.

5 **MS. WAGSTAFF:** Dr. Sawyer, Dr. Mills and Johnson. And
6 then we have --

7 **THE COURT:** You will get those this week.

8 **MS. WAGSTAFF:** Okay.

9 And then we have a list of designations -- people we will
10 bring by video designation. And I believe we have -- we have
11 been exchanging, behind the scenes, Phase Two designations.
12 And we just received a couple objections last night for three
13 from Ms. Rubenstein, so we can get that ball rolling. We
14 understand that it was a little bit behind in Phase One. We
15 will get that rolling.

16 **THE COURT:** Yeah. The thing that is very -- one of
17 the challenging things about this trial is that, you know, the
18 deposition designations were due on a certain date, and they
19 didn't come in on that date. And most of them haven't come in
20 until the trial started. So I have been reading deposition
21 testimony while I have been hearing live testimony, and it is
22 very hard to keep track of what has come in already and what
23 hasn't.

24 I remember making a comment that -- I think I said
25 something to the effect of, Well, Monsanto has already elicited

PROCEEDINGS

1 testimony in this case about Hardeman being in remission. And
2 that was -- and then I thought about it, and I realized that is
3 not true. I read testimony -- I read proposed testimony about
4 Hardeman being in remission, but Monsanto hadn't actually put
5 that evidence in it. So it is very challenging.

6 So, you know, I would like to have -- I understand that
7 this trial is very challenging for everybody; but I would like
8 to try to have a more firm deadline for getting the depo
9 designations in for Phase Two.

10 **MS. MOORE:** We agree, Your Honor. And completely
11 understand what the Court is saying on that.

12 We have exchanged deposition designations for all the
13 depositions. We need to schedule meet-and-confers on
14 Phase Two, and we can do that this week.

15 And if we could, we could come back with a proposal
16 tomorrow, Your Honor, after the parties meet and confer to see
17 what makes the most sense on a firm deadline.

18 **THE COURT:** It would be my -- my tentative inclination
19 would be to require you to submit depo designations by, like,
20 Sunday or something.

21 **MS. MOORE:** That wouldn't be a problem, Your Honor.

22 **THE COURT:** For Phase -- all depo designations for
23 Phase Two due on Sunday. And I assume that it sounds like we
24 are going to have probably two more days of the Plaintiffs'
25 case on causation. And then, what, like two days of Monsanto

PROCEEDINGS

1 putting on its case, causation. Does that sound about right?

2 **MR. STEKLOFF:** My sense -- and we were conferring
3 about this based on the delay today -- is that the Plaintiffs
4 will rest -- that we will start our case on Wednesday, and so I
5 think --

6 **THE COURT:** So Tuesday and most of Wednesday will be
7 Weisenburger and Reeves and Farmer?

8 **MS. WAGSTAFF:** And Mr. Hardeman.

9 **THE COURT:** And Hardeman.

10 **MS. WAGSTAFF:** The Reeves' cut, I believe, is around
11 an hour. It is hovering around there. The Farmer is around
12 five minutes. Mr. Hardeman we think in total will take less
13 than an hour. And that leaves Dr. Weisenburger, and that is
14 the big unknown. But we think that if we put him up Tuesday
15 morning, we think that Monsanto will be putting on witnesses
16 either right before or right after lunch on Wednesday.

17 **THE COURT:** Okay. And then so do you have a sense --
18 I mean, obviously you can't predict how long cross-examination
19 is going to be and stuff, but I have sort of chopped Dr. Arber
20 a little bit. You have Arber, Levine.

21 **MR. STEKLOFF:** Levine and Mucci.

22 **THE COURT:** And Mucci.

23 So closings on Phase One may take place in the first half
24 of next week, sounds like.

25 **MR. STEKLOFF:** I think they will probably take place

PROCEEDINGS

1 on Monday. I mean, depending on -- I think our case will take
2 about -- if we start on Wednesday, I think we will fill Friday,
3 and then depending how long the crosses are maybe go a little
4 bit into Monday but not much more. I don't know if we have --
5 if we rest that day, how Your Honor wants to deal with it, if
6 you want to do closings all day.

7 **THE COURT:** I think if the evidence bleeds over into
8 Monday, I think it would be fine just to tell you-all that you
9 don't have to close immediately at the -- once the evidence --
10 once you rest. There may be some rebuttal testimony from the
11 Plaintiffs. But in any event, even if there is not, if you
12 want to just wait until Tuesday morning to do your closings,
13 that's fine.

14 **MS. WAGSTAFF:** That would be fine, Your Honor.

15 **THE COURT:** And then I will get you a draft, you know,
16 an updated draft of the jury instructions for Phase One
17 shortly.

18 **MS. MOORE:** And that brings up a good point,
19 Your Honor. We also need to re-visit about a deadline for jury
20 instructions for Phase Two. Remember, we put that off. So
21 when would you like us to propose jury instructions for
22 Phase Two in the event we get through Phase One?

23 **THE COURT:** I'm more concerned with the depo
24 designations. I want you to get those in on time. So I don't
25 want you to be distracted by the jury instruction project while

PROCEEDINGS

1 you are working on the depo designations.

2 So, you know, I would say that if -- I mean, I'm happy to,
3 you know, be corrected on this; but I think it would probably
4 be okay to wait until, like, Thursday of next week for you to
5 get jury instructions in for Phase Two.

6 **MS. MOORE:** That sounds fine, Your Honor.

7 **MS. WAGSTAFF:** Your Honor, just one logistical
8 question: If we -- if the jury comes back with a positive
9 finding on causation, we will start opening the following
10 morning?

11 **THE COURT:** Correct.

12 **MS. WAGSTAFF:** Okay.

13 **MR. STEKLOFF:** The only issue I have, Your Honor, on
14 Phase Two jury instructions is that how you rule on that design
15 defect issue --

16 **THE COURT:** Yes.

17 **MR. STEKLOFF:** -- could impact openings for Phase Two,
18 because I think whether it is consumer expectation or
19 risk-benefit, probably goes to what would be said or
20 potentially said.

21 **THE COURT:** And my recollection is sort of a blur
22 right now, but my recollection is that you-all have argued that
23 point. You have submitted briefing on that question.

24 **MS. MOORE:** That's correct, Your Honor.

25 **THE COURT:** So it is probably -- I'm probably capable

PROCEEDINGS

1 of ruling on it in advance of the start of Phase Two, even
2 without putting -- without us hashing out jury instructions.
3 So I will do that.

4 **MR. STEKLOFF:** Okay. And then if we are done with
5 that, I have just one housekeeping issue.

6 **THE COURT:** Okay. So just to make sure we are in
7 agreement, so depo designations for Phase Two are due noon on
8 Sunday, okay.

9 Proposed jury instructions for Phase Two are due on
10 Thursday of next week, whatever date that is.

11 **THE CLERK:** March 14th.

12 **THE COURT:** I will get you your rulings on the
13 expert -- the Phase Two experts. I will do a ruling on the
14 design defect issue. I will submit an updated version of
15 Phase One jury instructions in the next couple days. And there
16 will, of course, be an opportunity to discuss those. Thursday
17 may be a day to discuss those. Monday afternoon may be a day
18 to discuss those. We will see -- we will take a look at -- we
19 will see how the timing is working out.

20 **MR. STEKLOFF:** Your Honor, on the design defect issue,
21 I think this is right. So the issue came up in the motion in
22 limine context when discussing Plaintiff's motion to exclude
23 benefits.

24 **THE COURT:** I remember that.

25 **MR. STEKLOFF:** I don't think we have fully briefed the

PROCEEDINGS

1 legal -- the full legal issues that would be relevant to
2 Phase Two on that issue.

3 **MS. MOORE:** That's correct.

4 **MR. STEKLOFF:** So I don't know if maybe -- I think it
5 would be important for opening if we can separately brief that
6 by either late this week or early next week.

7 **THE COURT:** Why don't you -- I never allow
8 simultaneous briefs, but I will allow it this time. You can
9 file letter briefs on that issue by noon on Thursday.

10 **MS. MOORE:** Thank you, Your Honor.

11 **MR. STEKLOFF:** Thank you. And then --

12 **THE COURT:** That's this Thursday.

13 **MR. STEKLOFF:** Yes.

14 And then my housekeeping issue, Your Honor, is we went
15 back to check the medical records that were used during the
16 three doctor depositions, Mr. Hardeman's treating physicians,
17 on last week; and so we now would move into evidence TX38, 41,
18 42, and 43, which were played during Dr. Ye's deposition.

19 And then we -- on our end -- have a composite medical
20 record, so that is TX1023, and we would just move in specific
21 pages that were shown to the jury or discussed during the
22 deposition, sorry, which are pages 109 through 110, 113 through
23 115, 282 through 283, 381 through 382, 797 through 798, 841
24 through 861, and 1562 through 1564.

25 And we have -- we have and will send redacted versions of

PROCEEDINGS

1 all of those to counsel so they can just verify the ones that
2 are actually sent back to the jury so that all of the personal
3 identifying information is redacted from those at the top of
4 all the medical records. It has that. So we would move those
5 into evidence.

6 **THE COURT:** Any objection?

7 **MS. MOORE:** Your Honor, we would like the opportunity
8 to actually see what those are. I don't recall off the top of
9 my head. With respect to the Dr. Ye depo exhibits, those are
10 likely fine. But these additional pages, I would like the
11 opportunity to review what they are before we -- before we say
12 whether we have an objection.

13 **THE COURT:** Okay.

14 **MS. MOORE:** Thank you, Your Honor.

15 **THE COURT:** On the issue of the sick juror, I think --
16 I'm assuming you-all will agree with this, but I just want to
17 make sure we are on the same page. If it is, in fact, food
18 poisoning, presumably she will be able to be back tomorrow. If
19 it is the flu, I assume she has to be excused, given the flu
20 that has been going around and knocking people out for over a
21 week.

22 Everybody agree with that?

23 **MS. MOORE:** Yes, Your Honor.

24 **MR. STEKLOFF:** Yes, Your Honor.

25 **MS. MATTHEWS:** Your Honor, we had one last issue

PROCEEDINGS

1 expecting Plaintiff Hardeman's testimony first thing in the
2 morning and --

3 **THE COURT:** So first thing, so he will be -- so the
4 plan for tomorrow is Hardeman will take the stand and then
5 Weisenburger?

6 **MS. MOORE:** Yes, Your Honor.

7 **THE COURT:** Okay. Sorry, one other question while I
8 have it on my mind.

9 And then Farmer -- we are all set on Farmer. We know what
10 is coming in on Farmer, correct?

11 **MS. MOORE:** Correct.

12 **THE COURT:** And then for Reeves, there is some further
13 argument that I need to consider from the parties about the
14 1985 mouse study?

15 **MS. MOORE:** Correct.

16 **THE COURT:** I have -- I have ruled on which aspects of
17 Reeves can come in subject to further argument on the mouse
18 study issue. And so the only thing for me to do with respect
19 to Reeves is to issue a ruling on that issue, correct?

20 **MS. MOORE:** That's right. I believe, Your Honor, and
21 we are prepared to do argument on that today, if the Court
22 would like.

23 **THE COURT:** Okay. I'm not sure I'm going to need it,
24 but I have -- you know, both parties have been heard through
25 their filings and all that, and -- but if I need it, I will let

PROCEEDINGS

1 you know.

2 **MS. MOORE:** Okay.

3 **THE COURT:** I will look at it this morning most
4 likely.

5 **MS. MOORE:** Okay. Thank you, Your Honor.

6 **THE COURT:** Is there anything else you need from me
7 with respect to Phase One, other than the stuff that I have
8 identified, the jury instructions and the Reeves thing and --

9 **MS. MOORE:** I don't think so, Your Honor. There were
10 letter briefs that were submitted last night regarding the
11 Reeves' issue.

12 **THE COURT:** Yeah.

13 **MS. MOORE:** I don't think so, Your Honor.

14 **THE COURT:** Okay.

15 **MS. MOORE:** I think that's enough.

16 **THE COURT:** Okay. And then you were going to say
17 something about Hardeman.

18 **MS. MATTHEWS:** Yes, Your Honor.

19 We have talked about potential exhibits that the Plaintiff
20 intends to use and we intend to use, and we have an objection
21 to Plaintiff's plan to bring a physical sprayer into the
22 courtroom. Monsanto's objection is on Rule 401 and 403
23 grounds. We fully expect Mr. Hardeman to testify about his
24 Roundup use.

25 The concern about the sprayer harkens back to the pretrial

PROCEEDINGS

1 conference on February 13 where Dr. Sawyer, Plaintiff's expert,
2 conducted no exposure analysis whatsoever. The concerns that
3 bringing in the physical sprayer into the courtroom will invite
4 the jury to try to make some sort of supposition or conclusion
5 about the nature of how Mr. Hardeman used the Roundup, and
6 there isn't an expert that has testified on that. That issue
7 is not germane.

8 So that is our concern with the physical sprayer bringing
9 brought to the courtroom.

10 **THE COURT:** You made reference -- it seems like you
11 were making reference to some discussion we previously had
12 about the sprayer. I don't recall any such discussion. Could
13 you remind me --

14 **MS. MATTHEWS:** No. Dr. Sawyer, their exposure expert,
15 who performed no exposure analysis with respect to
16 Mr. Hardeman. So our concerns that the physical sprayer will
17 invite the jury to try to speculate about how the nature of his
18 spraying could have had some impact when that is not what is at
19 issue in the case. So that's our concern with the physical
20 sprayer being brought into the courtroom.

21 **THE COURT:** Well, I guess I'm not fully understanding
22 the point you are trying to make about exposure. I want to get
23 a better understanding of that before I -- we turn to the
24 sprayer issue.

25 I mean, part of Dr. Weisenburger's opinion is that

PROCEEDINGS

1 Mr. Hardeman was exposed to a great deal of Roundup, right? Or
2 to be more precise, part of Mr. -- of Dr. Weisenburger's
3 opinion that Roundup caused Mr. Hardeman's NHL is the
4 assumption -- based on Hardeman's testimony -- that Hardeman
5 was exposed to a great deal of Roundup, right, not just a
6 little bit of Roundup, not just two lifetime days or ten
7 lifetime days or whatever.

8 And so obviously Hardeman can testify that he was --
9 about -- you know, the way he sprayed Roundup and the amount of
10 times he sprayed Roundup, how often, et cetera, to help
11 establish that he was exposed to a lot of Roundup, a lot more
12 than the floor that the experts were trying to -- that the
13 Plaintiff's specific causation experts were trying to
14 establish.

15 So given that Mr. Hardeman can testify about how he was
16 exposed to Roundup, what -- what is the -- what is --
17 specifically, what is the objection to sort of -- I guess it
18 sounds like your objection may be he can just describe using
19 the sprayer as opposed to bringing the sprayer in. Is that
20 what your objection is?

21 **MS. MATTHEWS:** Well, at the deposition there was a
22 picture, and we have not lodged an objection to the picture.
23 Now they said they intend to bring a physical sprayer. That
24 was not something that he authenticated or testified about
25 previously, but certainly there was a picture that was marked

PROCEEDINGS

1 as an exhibit; and we did not lodge an objection to the
2 picture.

3 **THE COURT:** So can you try to articulate for me what
4 is the -- so you are saying it is okay for them to use a
5 picture of the sprayer, but it's not okay to bring in the
6 actual sprayer?

7 **MS. MATTHEWS:** Well, I think the actual sprayer, the
8 question is whether it is going to invite the jury to speculate
9 about -- what about that sprayer could have had some role in
10 any purported exposure, and there is no testimony that is
11 supporting that would matter --

12 **THE COURT:** Why would it -- why would having the
13 actual sprayer invite such speculation more than having a
14 picture of the sprayer?

15 **MS. MATTHEWS:** Well, I think maybe we are down to what
16 is being done with the sprayer. Maybe it is just simply a
17 matter of it is here and visual, but we did want to flag that
18 issue in terms of what -- where it might lead. So I certainly
19 don't want to have to --

20 **THE COURT:** But I'm not understanding where it might
21 lead. I guess, I'm not understanding what the objection is.

22 Is it to talking about the sprayer? Is it to showing a
23 picture of the sprayer? Is it to having the actual sprayer in?
24 Or is it to what they might do with the sprayer if they bring
25 it in? I just don't -- I am not understanding what the

PROCEEDINGS

1 objection is.

2 **MS. MATTHEWS:** The objection would be to the physical
3 sprayer and how they might use it because the picture was not
4 something we contested, as we discussed.

5 **THE COURT:** Right. So putting aside the how they
6 might use it for a second, so your argument is that it is
7 permissible for them to use a picture of the sprayer; but they
8 should not be permitted to bring in the actual sprayer,
9 because --

10 **MS. MATTHEWS:** Because we are concerned about the 403
11 implications of whether it will invite the jury to make any
12 sort of speculation about how the use of the sprayer could have
13 influenced exposure where exposure is not something they have
14 offered an expert on and not something that we are even putting
15 at issue.

16 **THE COURT:** Okay. But if you could give me a couple
17 more sentences on how using the actual sprayer would invite
18 speculation in a way that using a picture would not invite
19 speculation.

20 **MS. MATTHEWS:** I think it would relate to the -- it
21 would be the use point, Your Honor. I think the question is,
22 you know, is this something that is just visually here for the
23 jury to see in place of the picture or is it something that is
24 going to be used in some way? And certainly we want to head
25 these issues off and not have to do something while the jury is

PROCEEDINGS

1 in the box, frankly. This is to just flag the issue, and the
2 concern is that visual representation of the sprayer stays
3 visual and doesn't become something more. And certainly that
4 is our concern, in making sure that at no point is the jury
5 then left to speculate about how a particular use of the
6 sprayer could have had an influence on what --

7 **THE COURT:** I mean, one helpful bit of guidance I can
8 provide now is that the Plaintiffs are not allowed to spray you
9 with the sprayer.

10 **MS. MATTHEWS:** Okay.

11 **THE COURT:** And they are definitely not allowed to
12 spray me with the sprayer. No matter --

13 **MS. MOORE:** We were not going to do that, Your Honor.

14 **THE COURT:** -- how much they would like to.

15 But other than that, I'm not just sure what I can say at
16 this point. I mean -- however, given what happened during
17 opening statements, I would be happy to require the Plaintiffs
18 to give me a, you know, step-by-step explanation of what they
19 plan on doing with the sprayer. And if something -- if, you
20 know, they describe something that is inappropriate, I can tell
21 them that they are not allowed to do it.

22 **MS. MOORE:** Your Honor, in all seriousness, the
23 sprayer is not going to have anything in it. Just to be really
24 clear, nobody is going to be sprayed in the room --

25 **THE COURT:** That's good.

PROCEEDINGS

1 **MS. MOORE:** -- although that is an interesting visual.

2 It is merely a demonstrative to help illustrate to the
3 jury and for Mr. Hardeman to explain, here is what I used, here
4 is how I mixed it and -- just -- it is a demonstrative. It is
5 here to help the jury. You don't need expert testimony for
6 that. It is just something for Mr. Hardeman --

7 **THE COURT:** No. I understand. But I want you to walk
8 me through it. What are you going to -- what is he going to
9 say about the sprayer and what are you going to do --

10 **MS. MOORE:** I'm going to ask him how he applied
11 Roundup. And he is going to say that he used a 2-gallon
12 pump-up sprayer.

13 And then I am going to ask him if this is similar to the
14 one that he used, and he is going to say yes.

15 How did you use this sprayer?

16 **THE COURT:** You are going to ask him to step down and
17 demonstrate how he used the sprayer.

18 **MS. MOORE:** Yes, Your Honor. It is not going to take
19 that long. That is basically in a nutshell what we are going
20 to do.

21 **THE COURT:** Okay. Tell me a little bit about the
22 sprayer. Is this something that goes on the back?

23 **MS. MOORE:** No. You carry it. It is a 2-gallon
24 pump-up sprayer. So it is a plastic 2-gallon thing -- do we
25 have it in the hallway? It is upstairs.

PROCEEDINGS

1 **THE COURT:** It's okay.

2 **MS. MOORE:** It is 2-gallon plastic. It has got a
3 plunger and you untwist the plunger. You pull that out. You
4 pour in the Roundup concentrate, and then you have water in
5 there. I think it is 4 to 6 ounces of Roundup concentrate to a
6 gallon of water. And that is what he is going to explain to
7 the jury he did. You put the plunger back in. You tighten it.
8 It locks in place, and it's got a little wand on it that you
9 use to spray.

10 **THE COURT:** Is there anything wrong with any of that?

11 **MS. MATTHEWS:** No. I think we are fine with that,
12 Your Honor.

13 **MS. MOORE:** Thank you, Your Honor.

14 **THE COURT:** Anything else?

15 **MR. STEKLOFF:** Just briefly, Your Honor.

16 In the Reeves' deposition I know the focus has been on the
17 1985 study. I think there are other pending objections, and if
18 we need to work -- for example, we have counters where I think
19 they have objected; and I don't think that there have been
20 rulings on those. So that's my understanding. I'm not trying
21 to litigate it now. I'm just flagging it as something that
22 needs to be resolved before Reeves can be played.

23 **THE COURT:** I thought I ruled on the counters also.
24 Did I not?

25 **MR. WOOL:** I don't believe so or not the entirety of

PROCEEDINGS

1 the counters.

2 **THE COURT:** Oh, okay. Hold on a second.

3 **MR. WOOL:** It is towards the very end of the
4 deposition.

5 **THE COURT:** Let's just make sure that I know what I
6 need to rule on.

7 (Whereupon, a brief pause was had.)

8 **THE COURT:** My recollection is that I tweaked this
9 ruling a little bit orally, right?

10 **MR. WOOL:** Correct.

11 **THE COURT:** I pulled up the written order that I filed
12 on March 1st. And then my recollection is that after going
13 through Farmer, I narrowed it a little bit more, right?

14 **MR. WOOL:** Correct.

15 **THE COURT:** So that's where we are now, right, on
16 Reeves?

17 **MR. WOOL:** Yes.

18 **THE COURT:** Okay. What more do you need me to do?

19 **MR. WOOL:** There are some Monsanto counters -- and
20 don't quote me on this -- but I think they begin at 784 and
21 continue from there. I don't think it's that big of a
22 designation.

23 **MR. STEKLOFF:** Agreed.

24 **MR. KILARU:** 739.

25 **MR. WOOL:** Oh, 739.

PROCEEDINGS

1 **THE COURT:** And then there were a couple other ones.
2 I'm looking at my order now, and I'm seeing pages 33 and 35.

3 It said, Overruled. Tentative argument needed.

4 Did we discuss that? Did we have argument on that?

5 **MR. WOOL:** We did not, Your Honor.

6 **THE COURT:** Okay. And then pages 544 to 546, I said
7 argument needed. Did we discuss that? We didn't resolve that
8 one yet either?

9 **MR. WOOL:** No.

10 **THE COURT:** Okay. Well, what I would propose that we
11 do actually is, if it is okay with you, why don't I go spend
12 another 45 minutes, let's say, with the Reeves stuff, and then
13 come back out and talk about it and kind of have a final
14 resolution with it?

15 **MR. STEKLOFF:** Sure.

16 I have one other question. We have time -- I guess, in
17 some way, but I don't want to prolong the day -- but Your Honor
18 said something about Dr. Weisenburger, and I don't know if now
19 is the time to address it. I also know that Your Honor issued
20 an order this weekend saying you needed to speak to
21 Dr. Weisenburger outside the presence of the jury.

22 **THE COURT:** Well, my idea on that was simply that we
23 should probably have one more discussion about *Hardell* and
24 *Eriksson* and the dose response issue to make clear what
25 Dr. Weisenburger can and can't say since it is a little

PROCEEDINGS

1 trickier with him given that he is offering both a general and
2 a specific causation opinion. And it seemed useful to have
3 that conversation with Ritz in the room last time, so I was
4 proposing that we just have the conversation with Weisenburger
5 in the room this time.

6 **MR. STEKLOFF:** I would agree with that, Your Honor.
7 What I think flagged the concern for me was -- so I think
8 Mr. Hardeman is going to come in. He is going to say he used a
9 lot of Roundup. And then Dr. Weisenburger is going to then say
10 somehow that that amount of -- whether he can say there was a
11 doubling of the risk based on *McDuffie* and *Eriksson* -- I don't
12 think he can say that -- but even the suggestion that somehow
13 Mr. Hardeman's exposure was -- I mean, I think he can say it
14 met this level of sufficient minimal exposure, whatever that
15 level is, but to say somehow -- to suggest that Mr. Hardeman
16 was in anyway at any sort of higher risk, that was not part of
17 his methodology.

18 You will recall that, in fact, during depositions he
19 testified --

20 **THE COURT:** Wait a minute. I don't -- I don't agree
21 with that. My pretty clear recollection of Dr. Weisenburger's
22 testimony was that you were -- you spent a lot of time
23 cross-examining him on this floor that he established. What I
24 concluded is, you know, sort of an artificial floor based on
25 these unadjusted numbers that is not appropriate.

PROCEEDINGS

1 But his main point was that Mr. Hardeman has been exposed
2 to so much more than that. It doesn't really matter what the
3 floor is. And, you know, the greater the exposure, the greater
4 the risk. And that point I think is -- I think he is allowed
5 to make that point, and I think that the point that I was
6 trying to make in my rulings on specific causation is that --
7 you know, the general point that risk increases with greater
8 exposure can be made by the general causation experts based in
9 part on *McDuffie* and *Eriksson*; but -- and I think I misspoke
10 earlier and said *Hardell* and *Eriksson*, but I meant *McDuffie* and
11 *Eriksson* -- that basic point can be made. And so the specific
12 causation experts can build on that specific point when they
13 are applying this to Mr. Hardeman, but what the specific
14 causation experts cannot say is that -- is that there is a
15 quantification that can be attached to the risk of somebody who
16 uses Roundup a specific amount.

17 **MR. STEKLOFF:** But even with the first part, to say
18 that he has -- he is at a much higher risk because he had so
19 much Roundup use, you may recall from the hearing that he tried
20 to make that point, tying it initially to *McDuffie* and
21 *Eriksson* with saying it is more than -- he used it more than
22 two days per year. He used it more than ten days.

23 Your Honor then pushed back and said, Well, in those
24 studies that was a -- that's where they divided the dose
25 response question. But, in fact, there were people in the

PROCEEDINGS

1 group using introspective study more than two days or more than
2 ten days who well exceeded those levels. It wasn't as though
3 they only used it for two days or ten days.

4 And towards the end of the hearing -- I don't have it in
5 front of me -- Your Honor questioned him and said, Well, isn't
6 this what you said, Dr. Weisenburger?

7 And he said, Maybe I shouldn't say that because he
8 conceded --

9 **MS. MOORE:** That is different.

10 **THE COURT:** It seems to me that you are just
11 re-arguing the specific causation ruling that I already issued.
12 Because what I said is that -- the point I made, and I think I
13 made it quite clearly in the specific causation ruling -- is
14 that yes, in response -- that is not the core of
15 Dr. Weisenburger's opinion. That was the -- that was the focus
16 of the discussion in your cross-examination of
17 Dr. Weisenburger, but it is not the core of his opinion when
18 you go back and you read his report.

19 And when you go back and read his report, the takeaway is,
20 you know, he got exposed -- Hardeman was exposed to Roundup a
21 lot. And the risk of -- the risk of getting NHL from Roundup
22 increases with exposure, and so -- all -- I'm -- in
23 cross-examination there was a lot of focus on this issue, and
24 I'm saying you won on that issue.

25 But that does not prevent Weisenburger from testifying

PROCEEDINGS

1 that -- that, you know, the risk increased. I made very clear
2 in my specific causation ruling that Weisenburger's opinion,
3 which is admissible, is based in significant part on the
4 significant exposure that Mr. Hardeman experienced.

5 So -- but all of that is to say that we -- you know, we
6 should lay the ground rules for Dr. Weisenburger, and the
7 ground rules I think are that he can say what *McDuffie* and
8 *Eriksson* said in his general causation opinion. He can say
9 that -- as part of his general causation opinion that there is
10 a dose response and that there is reason to believe that the
11 greater the exposure, the greater the risk.

12 In his specific causation opinion, he can testify that
13 because Hardeman was exposed so much, you would expect --
14 that's part of the reason why he doesn't rule out Roundup. But
15 what he cannot do during his specific causation opinion is
16 quantify the risk that -- that Mr. Hardeman experienced or
17 otherwise attempt to attach numbers to the -- to the risk that
18 somebody experiences based on the amount of glyphosate that
19 they were exposed to.

20 **MS. MOORE:** I understand, Your Honor.

21 And if the Court would like, we should be able to, given
22 our -- Mr. Stekloff and I talked on a break that -- even with
23 cross, that Mr. Hardeman will be on the stand less than an
24 hour. It might be a good time to break. You would have five
25 minutes alone with Dr. Weisenburger before he testifies. We

PROCEEDINGS

1 understand the Court's ruling.

2 **THE COURT:** Okay. Anything else?

3 **MR. STEKLOFF:** No, Your Honor.

4 **MS. MOORE:** Not from us, Your Honor.

5 **THE COURT:** Okay. So why don't I --

6 **MR. BRAKE:** I'm sorry, Your Honor. Brian Brake.

7 The reason I'm approaching you is to make sure we have a
8 definitive date for the next bellwether trial. And I assume
9 that is the Stevick complaint. I have on my calendar May 6th.
10 I don't have an order or something that definitively says that
11 is the date, so I wanted to confirm before we start making
12 plans that that is the date or if that's not the date, what the
13 date is.

14 **THE COURT:** Yeah, that's a good question. And I have
15 been reflecting on that. And I'm happy to hear discussion from
16 both sides on this question.

17 I have been sort of wondering -- I mean, if -- if this
18 case -- if this trial -- this Hardeman trial were to end in a
19 mistrial, if the jury could not reach a verdict on the question
20 of causation, for example, I would think that we would want to
21 go back and do -- and re-try the case in May on this date that
22 we have identified.

23 **MR. BRAKE:** I see.

24 **THE COURT:** That's number one.

25 Number two, is if that doesn't happen, if there is a

PROCEEDINGS

1 verdict either in favor of Monsanto or a verdict in favor of
2 Hardeman, you know, one of the things I was pondering is, Well
3 at that point there will involve this Johnson verdict. There
4 will have been this verdict. There will have been, presumably,
5 a verdict in the Alameda County Superior Court case, which is
6 scheduled to begin, when?

7 **MS. WAGSTAFF:** March 18th.

8 **THE COURT:** March 18th. And have they budgeted -- how
9 much time have they budgeted for that case? Does anybody know?

10 **MS. WAGSTAFF:** I think that they have budgeted a week
11 for jury selection with openings to start March 25th, and then
12 I think they have budgeted around six weeks, seven weeks.

13 **MR. BRAKE:** I think that is approximately correct,
14 Your Honor.

15 **THE COURT:** Okay. I wonder -- I mean, just -- you
16 know, it is sort of artificial to focus only on the federal
17 cases. I mean, if the idea is that, you know, we want to try
18 enough cases, enough bellwethers, to give the parties a sense
19 of sort of how to structure settlement discussions, I wonder if
20 those three will be enough. And I wonder if those -- at that
21 point, after we have those three verdicts, if it might make
22 sense to press the pause button a little bit for both sides;
23 allow both sides to sort of figure it out how they want to
24 approach settlement issues, such that Ms. Stevick doesn't need
25 to go to trial in May.

PROCEEDINGS

1 That is just sort of a musing at this point. That is
2 not -- I'm not expressing a view either way. I'm happy to
3 allow the parties to sort of go back and think about it and see
4 what they want to say to me about it, but it seems to me that
5 that is one reasonable approach to all of this.

6 And I understand that you are under a lot of pressure to
7 get ready for trial and so you would want an answer on that
8 question fairly soon.

9 **MR. BRAKE:** Yes. I just need to know whether I'm
10 going or not and when, so I can do what I need to do. But I
11 think that Your Honor's suggestion may make some sense about
12 waiting to see. I would just like to have some clarity as to
13 what Your Honor wants to do sooner rather than later.

14 **THE COURT:** And then we can also -- I mean, that
15 wouldn't mean putting off the Stevick trial for a long time.
16 It would just mean -- maybe it would be in the fall, for
17 example, as opposed -- or in the late fall or something like
18 that, as opposed to May.

19 But I'm -- I'm available to do it in May, so, you know,
20 that's -- you know, maybe we should just plow ahead and be
21 ready to do it in May. But I will let everybody kind of think
22 about that a little bit. And why don't we all pledge to figure
23 that out by the end of this week. How is that?

24 **MR. BRAKE:** Yes, sir. And we can confirm the May 6th,
25 not necessarily right now, but May 6th is the date that it will

PROCEEDINGS

1 go, if it does go. I don't need to know right this moment, but
2 that is one thing I want to confirm.

3 **THE COURT:** Yeah. And I will take a look at how the
4 calendar has evolved since we set that May 6th date, but I
5 think the answer is probably May 6th. Maybe not. We will -- I
6 will take a look at what else is on there.

7 **MR. BRAKE:** Thank you.

8 **MS. WAGSTAFF:** Your Honor, just because it sounds like
9 you might be interested in this information, my law firm has a
10 hard trial date of October in a Montana state court case. We
11 also had a trial date --

12 **THE COURT:** You mean, in a Roundup?

13 **MS. WAGSTAFF:** Yes, I'm sorry. I'm just talking about
14 Roundup cases because I thought you might be interested.

15 **THE COURT:** Yeah.

16 **MS. WAGSTAFF:** We also had a trial date starting in
17 April in St. Louis County that has been moved because the judge
18 recused himself. We are trying to get a summer trial date.

19 I think that Ms. Greenwald's firm has an October trial
20 date in St. Louis City.

21 I believe that your law firm has -- when is the Hall trial
22 date? I think that --

23 **MR. BRAKE:** It is coming up, but I'm not exactly sure
24 at this moment.

25 **MS. WAGSTAFF:** In St. Louis City. And then I think

PROCEEDINGS

1 that there are just going to be trial dates rotating, starting
2 almost immediately after one finishes.

3 **THE COURT:** Well, that may -- I mean, one thing we
4 will not do is we will not refrain from scheduling a trial in,
5 say, October because there is a state court trial scheduled in
6 October, because then the state court trial gets moved and we
7 have -- we have missed the opportunity to have a trial at that
8 time. Nobody -- neither goes to trial, and, you know, we are
9 still going to be here ten years from now not having tried any
10 cases. So that's one issue.

11 And maybe all of this is an argument for just plowing
12 ahead in May, but I think mainly the parties should go back and
13 start pondering that. And we will talk about that later this
14 week.

15 **MS. WAGSTAFF:** Sure.

16 **MR. BRAKE:** Thank you, Your Honor.

17 **THE COURT:** Why don't I spend, say, around 45 minutes
18 on the Reeves stuff, and then -- so why don't we -- unless you
19 hear from Kristen otherwise, why don't we plan on resuming at
20 10:30 to talk about the Reeves stuff. Okay?

21 **MS. MOORE:** Thank you, Your Honor.

22 **THE CLERK:** Court is in recess.

23 (Recess taken at 9:45 a.m.)

24 (Proceedings resumed at 10:45 a.m.)

25 (Proceedings were heard out of presence of the jury:)

PROCEEDINGS

1 **THE COURT:** Okay. So we have the Reeves' testimony,
2 and we have the mouse study, which is related to the Reeves'
3 testimony.

4 On the topic of the mouse study, my view is that, you
5 know, I don't think it is appropriate to force the Plaintiffs
6 into the kind of stipulation that the Defendants have proposed.
7 I think they have to be allowed to put in evidence to establish
8 this point. I don't think you can force them to do it by way
9 of a stipulation or at least in this context, I don't think it
10 would be appropriate to do that.

11 So I think really what the discussion is about, for the
12 mouse study is, you know, is there a way to further limit the
13 testimony that is coming in about it while still allowing the
14 Plaintiffs to present their whole story? And so that's really
15 what I want to focus the discussion on here is that portion of
16 Reeves' testimony regarding the mouse study and whether there
17 is a way to narrow it.

18 I mean, you saw that I already took a number of steps to
19 narrow it. I sustained some of the objections to that portion
20 of the testimony about the mouse study. And, you know, the
21 question is whether there is a reasonable way to further limit
22 it.

23 You know -- so I will hear from you on that. But I just
24 went through it again, and although it is a little bit long
25 and, you know, it's -- you know, they hammer on it a bit, I

PROCEEDINGS

1 think perhaps it is reasonable because it is somewhat of a
2 complicated topic. So it does take a little bit of time to
3 explain.

4 But anyway, that's my -- those are my thoughts.

5 **MR. KILARU:** Sure, Your Honor. So I understand these
6 sort of stipulations can't be a one-sided affair.

7 **THE COURT:** By the way, one other thing I want to
8 say -- just so that it informs the discussion -- is I have now
9 looked at the counter-designations. I think for the most part,
10 the counter-designations are permissible. There will be some
11 chopping here and there; but I think for the most part, the
12 counter-designations are permissible.

13 And the stuff -- in particular the stuff that Reeves says
14 about the whole mouse study debacle, that -- all of the stuff
15 that you counter-designated about that, I think is appropriate,
16 subject to a couple of exceptions that I flagged that we can
17 talk about a little bit later.

18 **MR. KILARU:** Okay.

19 **THE COURT:** Okay.

20 **MR. KILARU:** Your Honor, I think in the main --
21 understanding your position on this, that makes sense. I think
22 the reason we had gotten into the stipulation was mostly
23 because the EPA piece does complicate things a little bit, just
24 because it puts EPA regulatory documents into the picture.

25 **THE COURT:** Yes.

PROCEEDINGS

1 **MR. KILARU:** So I think even -- I guess there is a
2 question of whether certain portions of the stipulations as to
3 what the EPA did might be admissible instead of Dr. Reeves
4 going through what the EPA memo said just because I don't think
5 we haven't -- understandably so -- gotten into sort of a fuller
6 version of the EPA story.

7 So that's one proposal that we offer.

8 **THE COURT:** Okay. So tell -- give me -- spell that
9 out for me a little bit. Let's go to the deposition testimony
10 and tell me what you are proposing taking out.

11 **MR. KILARU:** Sure. So I think -- let me go to -- so,
12 for example, if you start on page 217 -- 217 through 220 --

13 **THE COURT:** Wait. Hold on. Sorry. Let me get there.

14 **MR. KILARU:** Of course.

15 (Whereupon, a brief pause was had.)

16 **THE COURT:** Okay.

17 **MR. KILARU:** So 217 through 220 is a discussion of an
18 EPA document that basically summarizes the component of EPA's
19 position that glyphosate should be classified as a Category C
20 oncogene.

21 **THE COURT:** Yes.

22 **MR. KILARU:** That is a fact that we have at least
23 offered to stipulate to that based on its initial review of the
24 study -- this is point 3 in our stipulation -- our proposed
25 stipulation -- I think that is one way we can trim, avoid

PROCEEDINGS

1 having a lot of EPA testimony come in with something shorter
2 than that.

3 **THE COURT:** Right. But all of this -- all this does
4 is establish that there is this document that was signed onto
5 by this group of eight people, and it expresses a conclusion by
6 the EPA that -- or not -- by the panel.

7 **MR. KILARU:** Yes.

8 **THE COURT:** That glyphosate is a Category C oncogene.
9 It is not a decision made by the EPA writ large.

10 **MR. KILARU:** Right.

11 **THE COURT:** It is a decision made by the panel within
12 the EPA, the point that I assume is important for you to make.

13 **MR. KILARU:** Fair enough, Your Honor.

14 **THE COURT:** And so I think that's -- I would assume
15 that this document would not be admitted into evidence.

16 **MR. KILARU:** Okay.

17 **THE COURT:** But you would be able to pull out the
18 portions of the document that they do, in fact, pull out in
19 this excerpt and put that in front of the jury.

20 **MR. KILARU:** Okay. That's understood, Your Honor.

21 **MR. WOOL:** Thanks.

22 **MR. KILARU:** I think there are just a few other --

23 **THE COURT:** Sure.

24 **MR. KILARU:** -- short things that we proposed, not as
25 much based on the substance, but based on the nature of the

PROCEEDINGS

1 questioning and sort of where it leads to.

2 **THE COURT:** Okay.

3 **MR. KILARU:** So one example is on page 229. There is
4 a section from line 7 through 14.

5 **THE COURT:** Yeah.

6 **MR. KILARU:** It is sort of the attorney asking, you
7 know, sort of I think a pretty argumentative question about
8 whether someone is speculating in the document. The witness
9 says that's not all there is. But I think that exchange
10 probably doesn't add much to the discussion.

11 **THE COURT:** Well, except that his testimony --
12 testimony preceding that question is an effort to kind of
13 downplay the import of the document and so I think the attorney
14 here is -- Mr. Wisner is kind of pushing back on that, and I
15 don't know -- I didn't find that to be particularly
16 inappropriate.

17 **MR. KILARU:** I guess on that, Your Honor, I think I
18 recognize it as it is a short section, but I think in context
19 there is sort of -- you know, there has been a fair amount of
20 questioning going in front of -- listing, if you go even back
21 to page 224 -- everything the document says, this point about
22 FJ. And we continue on, What can we do to get this thing off
23 Group C? This whole statement is in the document. I suspect
24 Plaintiffs have arguments they want to make about that. I
25 don't know that that sort of an attorney question speculating

PROCEEDINGS

1 about what's meant by that and an answer that doesn't really
2 confirm or deny it, doesn't add much to the discussion about
3 what the document says.

4 **THE COURT:** Okay. But where earlier does it say
5 that's what the document says --

6 **MR. KILARU:** 227, Your Honor at the bottom, it says --
7 line 20, it says, FJ asked, quote, short of a new study or
8 finding tumors in the control group, what else can we do to get
9 this thing off of Group C?

10 He says, It appears that in a meeting with EPA, FJ was
11 asked short of finding a tumor in this control group, what
12 would get this thing off of Group C.

13 So it is in there twice. And the witness points out other
14 things that are in the document. And there is another question
15 about how they didn't have the data yet.

16 **THE COURT:** Okay. I understand your objection, but
17 that's overruled.

18 **MR. KILARU:** Okay.

19 **THE COURT:** That can come in.

20 **MR. KILARU:** Okay. Turning to page 243, Your Honor,
21 starting at line 22, there is a -- I think pretty extensive
22 exchange -- maybe it is not that extensive. It is not that
23 extensive. I shouldn't have said that. But actually starting
24 at page 241 through 244, there is sort of back-and-forth about
25 whether it would be appropriate for Monsanto and Dr. Kushner

PROCEEDINGS

1 to have an opinion about the slides before they come in.

2 **THE COURT:** Yes.

3 **MR. KILARU:** And there is sort of extensive colloquy
4 about that question. And then sort of the witness says, I
5 would like to see a document.

6 **THE COURT:** Yeah.

7 **MR. KILARU:** I think as a general matter in Phase One
8 from Monsanto's position on the science and on sort of what
9 would be appropriate and not appropriate testing hasn't been
10 something that has been admissible. And I think this question
11 goes very much to that issue, and I think what follows is
12 actually discussion of the memo to Dr. Kuschner and some other
13 documents that Mr. Wisner presented. I think subject to our
14 broader objection, which I understand you overruled, we don't
15 have any further objection to the documents and the
16 back-and-forth coming in, so I think this portion of the
17 colloquy should be excluded.

18 I think that probably it is best said that it starts on
19 page 241, line 23 and goes through 244, line 21, because they
20 then proceed in the next portion to talk about the actual
21 documents themselves; and Mr. Wisner lays out a timeline that
22 he believes supports the position that he had, I think, sort of
23 had been arguing for in the back-and-forth.

24 **THE COURT:** Okay. I understand that, but I think this
25 exchange is relevant to the credibility of the witness and so

PROCEEDINGS

1 I'm overruling that objection.

2 What is next?

3 **MR. KILARU:** The last one, Your Honor, is on page 266
4 lines 12 through 20. I think this is pretty similar to the
5 first objection I raised, so I won't belabor the point; but
6 there is sort of a short colloquy about why someone is putting
7 a word in quotation marks or not. I actually don't even think
8 the answer to the witness' question is -- one of the
9 definitions of quotation marks means that's not really what I'm
10 saying, right? And the witness' answer isn't designated. I
11 think that is all pretty speculative and argumentative.

12 **THE COURT:** Okay. So tell me again where you want me
13 to look.

14 **MR. KILARU:** Sure. 266 lines 12 through 20.

15 **THE COURT:** Okay. No. I think that's -- that's --
16 this is -- this is in reference to a statement by Surdi from
17 the EPA?

18 **MR. KILARU:** Yes.

19 **THE COURT:** I think that does call for speculation.
20 That has to come out.

21 So that is 266, lines 12 through 20.

22 **MR. KILARU:** That's right.

23 **THE COURT:** Yeah, that comes out.

24 **MR. KILARU:** I think, Your Honor, that would be it
25 subject to, of course, I think our counters to complete this

PROCEEDINGS

1 story; and we think that is important. But I know you said you
2 want to discuss that next, so --

3 **THE COURT:** Yeah, hold on a second. Let me pull out
4 the counters.

5 (Whereupon, a brief pause was had.)

6 **THE COURT:** Most of these I don't need discussion on.
7 I'm just flipping through where I had questions and then I want
8 to discuss with you.

9 (Whereupon, a brief pause was had.)

10 **THE COURT:** Most of these I don't need discussion on.
11 I'm just flipping through to see where I had questions or an
12 opinion that I wanted to discuss with you.

13 (Whereupon, a brief pause was had.)

14 **THE COURT:** Okay. So on the portions of the testimony
15 that Monsanto designated as a response on the issue of the
16 mouse study, my pretty strong inclination -- I'm going to go
17 back and read it one more time -- but my pretty strong
18 inclination is that all of that stuff comes in. So if there is
19 anything in particular you want to express a beef with, I will
20 give you an opportunity to do that now.

21 And then after that, I wanted to ask about -- the other
22 two things I thought were worth discussing were the one on
23 page 797 about long-term carcinogenicity studies, and the one
24 about -- on page 817 about Acquavella.

25 **MR. KILARU:** Sorry, Your Honor. I might have the

PROCEEDINGS

1 pages wrong. I don't believe 797 was designated.

2 **MR. WOOL:** No.

3 **THE COURT:** 797 was not designated?

4 **MR. KILARU:** I don't have it as designated. I think
5 we actually pulled that. It might have been earlier
6 designated, and we actually pulled that.

7 **THE COURT:** So you pulled that. Okay. Good.

8 **MR. KILARU:** Yeah.

9 **THE COURT:** Then what about 817?

10 **MR. KILARU:** Yes. We -- this we did continue to
11 designate because I think it is sort of a response to the
12 questions asked of both this witness and then of some other
13 witnesses about the '97 Acquavella memo.

14 **THE COURT:** Okay. So that's -- I want to talk about
15 that one. Then go ahead.

16 Anything from you on the counter-designations?

17 **MR. WOOL:** On the counters, with respect to the
18 *Knezevich & Hogan* study, I mean, I'm not seeing anything that
19 we would really quarrel with in this little section.

20 **THE COURT:** Okay.

21 **MR. WOOL:** Then remind me again where you said you
22 were on the Acquavella.

23 **MR. KILARU:** 817, I believe.

24 **THE COURT:** Yeah, 817. So what I have -- this may be
25 an earlier version of what I have -- but -- sorry, an earlier

PROCEEDINGS

1 version of the designations. So I want to make sure I have it
2 right here. So I have on page 817, starting on line 5 there is
3 some text highlighted in orange.

4 **MR. KILARU:** Yes.

5 **THE COURT:** And then starting on page 818, going
6 through to page 822 --

7 **MR. KILARU:** Yes.

8 **THE COURT:** -- there is some text highlighted in
9 green. And then on page 823, it's again highlighted in orange.

10 **MR. KILARU:** That's right.

11 **THE COURT:** The orange is what again?

12 **MR. KILARU:** I think it's probably a coding issue as
13 much as anything else. This is all testimony that we would
14 propose to designate.

15 **THE COURT:** It is all what you want to designate?

16 **MR. KILARU:** Yes.

17 **THE COURT:** Okay. All right.

18 So help me understand this and how it relates to the AHS
19 stuff because it's -- you know, at first when I first started
20 looking at it, my reaction was, Okay. This is going to be
21 Monsanto's response to the Acquavella stuff. And then it
22 seemed to start to go beyond that, but I couldn't quite tell.

23 So talk me through this.

24 **MR. KILARU:** I think it talks about a different topic,
25 which is this exposure study, but I think it is in the context

PROCEEDINGS

1 of the response to the AHS, which is why we view this as tied
2 together. So one of the critiques in the memo is about sort of
3 inaccuracy or unreliability of the exposure data that will be
4 collected by the AHS based on the methods and practices that
5 they are using. I think that's one of the things that was in
6 the Acquavella internal memo.

7 **THE COURT:** Yes.

8 **MR. KILARU:** The questioning here -- sorry, what was
9 that?

10 **THE COURT:** I said "yes." Sorry.

11 **MR. KILARU:** So the questioning here then goes on and
12 talks about -- see in lines 817 to 818, what did the people who
13 were conducting the AHS, did they respond to these criticisms
14 that were in the memo.

15 **THE COURT:** Yeah.

16 **MR. KILARU:** And what follows is sort of a discussion
17 of how the AHS folks looked at their survey sort of in response
18 to those critiques that have been voiced in Dr. Acquavella's
19 survey -- in Dr. Acquavella's memo, and then it sort of
20 continues. There is a study that Monsanto did to sort of help
21 improve the methods of the AHS regarding this farm family
22 exposure study, which looked at the doses that farmers were
23 getting and how those -- to sort of make sure that what the AHS
24 was looking at was consistent with what was sort of happening,
25 I guess, more broadly in terms of farming.

PROCEEDINGS

1 **THE COURT:** Okay. Why isn't -- to the extent that
2 the -- to the extent that the folks who were conducting the
3 Farm Family Health Study addressed the concerns expressed by
4 Acquavella, and to the extent they did a good job of addressing
5 those concerns, why wouldn't Mucci testify to that? I mean,
6 why couldn't you just put -- why couldn't you just put the --
7 you don't even have to put the Acquavella memo in front of her,
8 because I assume you wouldn't want to.

9 You could say, you know, This concern has been expressed
10 about the AHS and what did -- what did the AHS folks do to
11 respond to that, and have her testify about that.

12 **MR. KILARU:** It is certainly another way to do it,
13 Your Honor, but I think several Monsanto witnesses have now
14 been asked about this memo; and so we thought having Monsanto
15 respond to it would be useful.

16 **THE COURT:** I think the problem is that at some point
17 it sort of bleeds into -- it seems to bleed into Reeves
18 offering expert testimony. You know, I mean, we are getting
19 into -- you know, on the one hand we have Monsanto's criticisms
20 of the AHS, and we didn't really get into whether those
21 criticisms were valid or anything along those lines. It is
22 just the fact that Monsanto had a person who was offering
23 criticisms of the AHS. Then it is for the experts to argue
24 about whether particular criticisms are valid or not.

25 And it seems like here we have got kind of Reeves being

PROCEEDINGS

1 drawn into an analysis of the AHS and the reliability of the
2 AHS and the methods used by the people who are conducting the
3 AHS, and that seems to be beyond the scope of what Reeves is
4 supposed to be testifying about. And so I think it's probably
5 fine to have Mucci do this, but I think this testimony -- my
6 sense is that it goes beyond the scope.

7 **MR. KILARU:** That's fine, Your Honor. I think it is
8 consistent with the rulings you have had earlier about experts
9 and so we can pull it down for that purpose.

10 **THE COURT:** Okay. So I think that means everything
11 after 817 goes; is that right?

12 **MR. KILARU:** Yes. And I actually don't think there
13 was anything else through the rest of the deposition, so I
14 think -- I think that would end the designations at that point.

15 **THE COURT:** Okay. Any problem with that concept of
16 Mucci being able to address that?

17 **MR. WOOL:** Right. I think that makes more sense, and
18 it is consistent I think with PT089, so --

19 **THE COURT:** Which one was PT089?

20 **MR. WOOL:** That was the one where Your Honor excluded
21 testimony by Reeves that was commenting on the relevant
22 scientific articles.

23 **THE COURT:** Okay. All right. So that -- so I will --
24 I will issue an order on Monsanto's counters, which just -- let
25 me be clear -- they begin at -- those begin at page 739,

PROCEEDINGS

1 correct?

2 **MR. KILARU:** Yes, Your Honor.

3 **THE COURT:** Okay. So I will issue an order on that.

4 As far as the stuff that the Plaintiffs designated for
5 Dr. Reeves, are we all on the same page?

6 **MR. WOOL:** I think there were two tentative rulings
7 that we might want to address.

8 **THE COURT:** Okay. But other than that, we are all
9 clear about what is coming in and what is not coming in between
10 pages 218 and 292, for example?

11 **MR. WOOL:** Yes. With respect to that, I think we are
12 clear.

13 **MR. KILARU:** Yes.

14 **THE COURT:** Okay. All right. So it is just these
15 loose ends that I -- that we need to tie up. And one was
16 pages 33 and 35, right?

17 **MR. WOOL:** Yes.

18 **THE COURT:** So my -- I went back and I looked through
19 all of this again this morning, and my reaction after doing so
20 would be that the designation on 33 could come in and the
21 designation on 35 should not come in.

22 **MR. WOOL:** And our argument with respect to the one on
23 35 is -- it sort of goes back to Portier and some questions he
24 got about EFSA, I think. And, you know, just sort of inputs
25 the genotox into perspective. Monsanto has emphasized a number

PROCEEDINGS

1 of times that it did not sponsor certain studies. And I think
2 this just sort of adds some context to the jury about how the
3 genotoxicity breaks down, and it sort of provides them with the
4 understanding that Monsanto has had a hand in a number of the
5 genotox studies.

6 And I think also there has been some -- a considerable bit
7 of testimony about NIH and kind of some of these other
8 organizations that are -- that are independent of Monsanto and
9 a real kind of push by Monsanto to put some emphasis on the
10 independent studies.

11 **THE COURT:** Okay. I understand that. I don't think
12 that 35 should come in given the state of the evidence.

13 **MR. WOOL:** Okay.

14 **THE COURT:** What is the problem with 33?

15 **MR. KILARU:** I think as a general matter, Your Honor,
16 with respect to the animal and the toxicological testing, who
17 sort of did the testing hasn't been that germane of an issue in
18 Phase One, so --

19 **THE COURT:** Well, it becomes more germane with this
20 issue that we have been talking about. So is there anything
21 inaccurate about the testimony that was --

22 **MR. KILARU:** I don't believe so, Your Honor. I think
23 to the extent it sort of ties to the mouse study, we can --

24 **THE COURT:** Okay. So that will be allowed.

25 **MR. KILARU:** Okay.

PROCEEDINGS

1 **THE COURT:** And then what was the other one?

2 **MR. KILARU:** I think it was 544; is that right?

3 **MR. WOOL:** Correct, yes.

4 **THE COURT:** 544. I forgot to go back and look at this
5 one this morning, so give me a second.

6 (Whereupon, a brief pause was had.)

7 **THE COURT:** Was 547, also -- was 547, 548 also
8 designated or was that withdrawn?

9 **MR. WOOL:** Yes. The sections on 547 at the bottom
10 starting on line 19 through 25 are designated, and then on 548,
11 line 1 through 7, and then again at 12 -- well, 12 by itself,
12 and then 16 through 25 were designated.

13 **MR. KILARU:** I think the testimony on this topic
14 actually goes through 555 --

15 **MR. WOOL:** Yeah, it continues.

16 **MR. KILARU:** It is sort of all the same topic.

17 **THE COURT:** So I guess, you know, my gut reaction to
18 this -- so this goes through 555, you said?

19 **MR. KILARU:** Yes.

20 **THE COURT:** I mean, the issue of dermal absorption
21 thus far has not become a contested issue in the trial, right?
22 So I'm -- I guess I'm scratching my head a little bit about
23 whether this should be admissible or not.

24 **MR. WOOL:** I think there are two issues this sort of
25 goes to. The first being the dose, and that is something that

PROCEEDINGS

1 came up with Dr. Portier on some. And, I believe, in opening
2 Monsanto made a statement to the effect of that the animals are
3 getting thousands and thousands times higher amounts of
4 glyphosate than humans will ever be exposed to in their life.
5 And I think that sort of goes to the --

6 **THE COURT:** But that is not contested to either,
7 right? Portier admits that too, right?

8 **MR. WOOL:** Well, yes, in terms of the dose itself; but
9 this goes to show that if humans do receive a substantial
10 dose -- I think that Mr. Hardeman's specific exposure is
11 probably going to be an issue that I think they probably -- I
12 would assume they are going to ask him about how much he
13 sprayed and that sort of thing. And this goes to the fact that
14 when he is spraying when he is getting exposed, it is actually
15 getting absorbed.

16 **THE COURT:** Well, but those are two different issues.
17 One issue is how much did he spray. I don't know whether they
18 plan on cross-examining him about that or not. But one issue
19 is how much did he spray. And the other issue is how was it
20 absorbed.

21 And thus far, at least as far as I can recall, the issue
22 of absorption has not been put into play. Like, nobody is
23 arguing -- so, for example, on the epidemiological studies,
24 right, we have *McDuffie* saying what she does. And we have
25 *Eriksson* saying what he says. And they talk about the -- you

PROCEEDINGS

1 know, the number of -- and we have the AHS talking about usage,
2 and we have the epidemiological studies sort of tied to -- some
3 of them tied to the amount of -- the number of times that
4 somebody used glyphosate, right?

5 **MR. WOOL:** Right.

6 **THE COURT:** But their conclusions do not depend at
7 all -- as far as I understand it -- anyway -- on the degree to
8 which the glyphosate can or cannot be absorbed through the
9 skin. They just -- they stop at the issue of how many times
10 did somebody use glyphosate.

11 **MR. WOOL:** Right.

12 **THE COURT:** And if I'm remembering that correctly, if
13 I'm right about all that, then I guess I'm not quite
14 understanding the relevance of this stuff about dermal
15 absorption.

16 **MR. WOOL:** Right. And maybe this is something that if
17 Hardeman is questioned extensively on actual exposure, how much
18 he got on his skin, you know, then I think maybe this would
19 come in. I think that if Monsanto sort of walks the line of
20 not getting into protective equipment or kind of his actual,
21 you know, not just the amount of times he used but his actual
22 exposure, then maybe we can keep this out for now.

23 But I think our thought was that they will probably cross
24 that line, and I think that at the point in time when they were
25 questioning Hardeman about the amounts of glyphosate he got on

PROCEEDINGS

1 his skin, et cetera, that it's useful for the jury to have a
2 sense as to how the glyphosate is being absorbed into the human
3 body.

4 **THE COURT:** Okay. And so one response I want to give
5 you is that I do think there is a difference between exposure
6 and absorption. So it's not clear to me that even if they
7 cross-examine him a lot about exposure, that that opens the
8 door to the discussion of absorption and -- but it's --
9 obviously, it is difficult to predict and difficult to consider
10 in the abstract. I mean, we have to see how he is
11 cross-examined. But that is a basic point that I'm not sure
12 I'm getting.

13 **MR. WOOL:** Well, I think this sort of kind of feeds
14 into the dose response that -- you know, you have exposure on
15 one hand. That obviously depends on what sort of protective
16 equipment you are wearing, but then how much is absorbed is
17 kind of the actual dose that you are getting and receiving and
18 so -- to --

19 **THE COURT:** The studies don't talk about dose response
20 in that way, do they?

21 **MR. WOOL:** Well, no. They don't talk about dose
22 response in that way. They do talk about the amount of
23 glyphosate that is being absorbed and ultimately excreted from
24 the human body.

25 **THE COURT:** The epidemiological studies?

PROCEEDINGS

1 **MR. WOOL:** No. I am just talking about the exposure
2 studies on the kind of the 550 range of the deposition.

3 **THE COURT:** Right. Right.

4 **MR. WOOL:** Did I misunderstand the question,
5 Your Honor? I'm sorry.

6 **THE COURT:** I'm just saying the epidemiology studies
7 don't talk about it in those terms. Maybe that is a flaw in
8 the epidemiology studies, but they don't talk about it in those
9 terms. Your case isn't based on -- you know, you have got your
10 three pillars of the science. You have got the epidemiology.
11 You have got the animal studies, and you have got the
12 mechanism. None of that seems to be tied to the issue of
13 absorption or at least the issue of absorption has not been
14 contested thus far.

15 **MR. WOOL:** Right, I think --

16 **THE COURT:** Another way to put it is the epidemiology
17 studies, for example, all presume that glyphosate is absorbed
18 somehow; and Monsanto has not done anything to question that as
19 of yet.

20 **MR. WOOL:** Right.

21 **THE COURT:** It seems.

22 **MR. WOOL:** And that sort of goes to my point. I think
23 we would probably concede that for, you know, the purposes of
24 an affirmative designation, maybe this doesn't come in right
25 now, but pending sort of what sort of questions Mr. Hardeman

PROCEEDINGS

1 gets, you know, then it may become relevant at that point.

2 **THE COURT:** Anything you want to say about that?

3 **MR. KILARU:** No, Your Honor. We agree that there is a
4 line that you have drawn between exposure and absorption. I
5 highly anticipate that our cross of Mr. Hardeman will stay on
6 the right side of that line.

7 **THE COURT:** Okay. You know, I mean, it may be that
8 I'm missing something when I say that there seems to me to be a
9 line between exposure and absorption, and maybe that -- it will
10 become apparent that I'm missing something when I hear the
11 cross-examination. But as I sit here now, I don't think this
12 is relevant to Phase One.

13 **MR. KILARU:** I don't think so, Your Honor. To the
14 question whether you are missing something, I think this
15 actually goes back to the debate we had before trial about
16 whether Dr. Sawyer would testify in Phase One. He is an
17 absorption expert. And I think that that is sort of a key
18 distinction between epidemiology and exposure versus absorption
19 on the other end, which we haven't made an issue of.

20 **THE COURT:** I remember that now.

21 **MR. WOOL:** And to be fair I think that there is a
22 slight distinction to be drawn on the absorption studies
23 between Roundup and glyphosate by itself -- which, again, I
24 don't know if it comes in in our case in chief -- but depending
25 on whether or not Monsanto crosses that line, I think it is

PROCEEDINGS

1 relevant.

2 **THE COURT:** Okay. Fair enough. So that will be out
3 for now.

4 Anything else to discuss with respect to Reeves or the
5 mouse study?

6 **MR. KILARU:** I think that's everything, Your Honor.

7 **MR. WOOL:** Nothing from the Plaintiffs.

8 **THE COURT:** Okay. So I will issue a ruling on the
9 counter-designations and -- just so you will have that -- like
10 all the preliminary stuff that we haven't talked about. And so
11 you will have that and it will be ready to go.

12 **MR. KILARU:** Thanks, Your Honor.

13 **MR. WOOL:** Thank you.

14 **THE COURT:** Anybody have anything else?

15 **MS. WAGSTAFF:** Yes, Your Honor.

16 Do you still have that packet for Dr. Martens that I
17 handed you?

18 **THE COURT:** I think so.

19 **MS. WAGSTAFF:** All right. I forgot that we actually
20 have an affirmative designation irrespective of the Parry
21 story.

22 **THE COURT:** Okay.

23 **MS. WAGSTAFF:** So there is actually two sort of
24 sections that we have designated. We are going to withdraw the
25 first section.

PROCEEDINGS

1 **THE COURT:** Okay.

2 **MS. WAGSTAFF:** So our designation that is affirmative
3 starts on page 235 of the -- if you are looking at it, at the
4 bottom, it is 235, but it is page 412 -- yeah, 235. It is in
5 purple.

6 **THE COURT:** Okay.

7 **MS. WAGSTAFF:** It starts with, Good morning,
8 Dr. Martens.

9 **THE COURT:** How far does it go?

10 **MS. WAGSTAFF:** To 238, about four pages. If you would
11 like to read it real quick.

12 **THE COURT:** Can I read it real quick?

13 **MS. WAGSTAFF:** Sure.

14 (Whereupon, a brief pause was had.)

15 **THE COURT:** Okay. So remind me who Martens is again.

16 **MS. WAGSTAFF:** He is a Monsanto toxicologist.

17 **THE COURT:** Okay.

18 (Whereupon, a brief pause was had.)

19 **THE COURT:** My reaction to this is this is for the
20 experts; this is not for the Monsanto witnesses. What am I
21 missing?

22 **MS. WAGSTAFF:** Yeah. So we would designate this
23 either as affirmatively or as rebuttal testimony, and I would
24 point you to where Monsanto was questioning Dr. Portier on this
25 specific topic, and they ask him: In the Knezevich study in

PROCEEDINGS

1 the high-dose group were exposed to 4,841 milligrams per
2 kilograms per day?

3 Yes, I do see that.

4 That is many, many fold higher than humans are exposed to,
5 correct? Many hundreds or thousands of fold higher, correct?

6 I really don't know.

7 You have not done that calculation?

8 I have not done that calculation.

9 Do you take issue with it being hundreds or thousands of
10 times higher than what humans are exposed to?

11 It is much higher. I will give you that.

12 And then they go on and on and ask him questions. So we
13 would say that this is a party -- a statement by a Monsanto
14 employee stating that actually that is completely in line with
15 the way the toxicology studies are done, and that the high
16 dosing is -- actually, there is nothing unusual about that, and
17 we think that Monsanto's cross-examination of Dr. Portier has
18 put that at issue.

19 **THE COURT:** But Monsanto's cross-examination of
20 Portier, as you read it to me, did not seem to be intended to
21 imply that this is unusual for toxicology.

22 **MS. WAGSTAFF:** Well, if you -- I guess it was the
23 inflection in his voice when he was asking it as well where he
24 was saying, You don't take issue with the fact that it is that
25 much higher. There is certainly suggestion that the high doses

PROCEEDINGS

1 that animals are given is unusual, and that was suggested in
2 the opening statement as well.

3 **THE COURT:** I don't -- I don't -- so, number one, I
4 don't recall that being the case.

5 But number two -- the more important point -- is that that
6 can be established -- and I understand your point that if
7 the -- if Monsanto, the company, said something different from
8 what Monsanto is saying at trial, then the statement by
9 Monsanto, the company, could come in. But I think your -- I
10 think the -- I think that the point you are making is far too
11 subtle to justify bringing in what is essentially expert
12 testimony from Dr. Martens on the issue of toxicology.

13 So I think it is appropriate to establish that through
14 examination and cross-examination of the experts, but I'm not
15 going to allow this testimony in.

16 **MS. WAGSTAFF:** Thank you, Your Honor.

17 **THE COURT:** All right. Anything else for today?

18 **MR. STEKLOFF:** Not from us, Your Honor. Thank you
19 very much.

20 **THE COURT:** Okay. Enjoy your day off.

21 **THE CLERK:** Court is adjourned.

22 (Proceedings adjourned at 11:29 a.m.)

23 ---oOo---

24

25

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25


CERTIFICATE OF REPORTERS

I certify that the foregoing is a correct transcript
from the record of proceedings in the above-entitled matter.

DATE: Monday, March 4, 2019



Jo Ann Bryce, CSR No. 3321, RMR, CRR, FCRR
U.S. Court Reporter



Marla F. Knox, RPR, CRR
U.S. Court Reporter